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1. INTRODUCTION 
 
1.1. Novel drug delivery system 1 
In the past few decades, considerable attention has been focused on the 
development of novel drug delivery system (NDDS). The NDDS should ideally fulfil 
two prerequisites. Firstly, it should deliver the drug at a rate directed by the needs of 
the body, over the period of treatment. Secondly, it should channel the active entity to 
the site of action. Conventional dosage forms including prolonged release dosage 
forms are unable to meet none of these. At present, no available drug delivery system 
behaves ideally, but sincere attempts have been made to achieve them through various 
novel approaches in drug delivery. 
 
Merits of novel drug delivery system 
9 Reduces the total amount of drug administered over the period of drug 
treatment, so it reduces the systemic and local side effects. 
9 Targeting of the drug molecule towards the tissue (or) organ reduces the toxicity 
to the normal tissues. 
9 Pulsatile and pH dependent systems release the drug whenever the body 
demands.  
9 Improved patient compliance resulting from the reduction in the frequency of 
doses required to maintain the desired therapeutic response.  
9 Devoid of gastrointestinal tract degradation and first pass metabolism.  
 
Limitations of novel drug delivery system 
9 To reach previously inaccessible domains e.g. intracellular site, bacteria, viruses 
parasites etc.  
9 To protect the drug and the body from one another until it reaches at the desired 
site of action.   
9 To control the frequency and rate of drug delivery at the pharmacological 
receptor.  
9 Reduction in the drug dose and side effects.  
9 Exclusive drug delivery to the specific cells or diseased site in the body.  
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1.1.1. Targeted drug delivery system 3,4 
Drug targeting can be defined as the ability to direct a therapeutic agent 
specifically to desired site of action with little or no interaction with nontarget tissue. 
Targeted drug delivery system means accumulation of pharmacologically active 
moiety at desired target site in therapeutic concentration at the same restricting its 
access to normal cellular lining, thus minimizing therapeutic index. In site specific 
targeted drug delivery, active drug is delivered to preselected and very specific 
compartments with maximum activity while reducing the concentration of drug to 
normal cells. The drug can be targeted to intracellular sites, virus cells, bacterial cells 
and parasites using different scientific strategies have proven very effective. 
Minimum distribution of the parent drug to the non target sites with higher and 
effective concentration at the targeted site certainly maximize the benefits of targeted 
drug delivery. 
   
Properties of ideal Targeted drug delivery 
•    It should possess controllable and predictable rate of drug release. 
• Carriers used should be inert or should have zero therapeutic value.  
• Carriers should be biodegradable and easily eliminated from the body. 
• The preparation of drug delivery system should be easy or reasonably simple,   
reproductive and cost effective. 
• Should be nontoxic and physicochemical stable in vivo and in vitro. 
• Drug release should not affect the drug distribution 
 
Targeted drug delivery systems are preferred under following situations, 
• Stability of the drug is poor. 
• Insoluble drugs. 
• Drugs which are having poor absorption,  
• Drugs with low specificity and low therapeutic index. 
• Drugs with short biological half life. 
• Drugs with large volume of distribution. 
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1.1.2. Types of drug targeting 4  
Passive Targeting 
In this type of targeting the particle system is captured by physiological 
mechanism such as filtration or macrophage (Reticulo endothelial system) 
sequestration. (i.e) drug targeting occurs because of the body’s natural response to 
physicochemical characteristics of the drug or drug carrier system. It is concentration 
dependent, so external energy is not necessary.  
 
Inverse Targeting: 
To achieve inverse targeting, RES normal function is suppressed by 
preinjecting large amount of blank colloidal carriers or macromolecules like dextran 
sulphate. This approach leads to saturation of RES and suppression of defense 
mechanism. This type of targeting is a effective approach to target drug(s) to non-RES 
organs. 
 
Active targeting: 
Surface modification technique is used to achieve active targeting. In this 
approach active ingredient is attached with the surface of carrier sytem such as 
monoclonal antibodies or carbohydrates like glucose and galactose. The drug reaches 
to specific site on the basis of modification made on its surface rather than natural 
uptake by RES. Active targeting is classified into three,  
 
і) First order targeting 
It involves distribution of drug carrier system to capillary bed of target site or 
organ. For example lymphatic’s, peritoneal cavity, plural cavity, cerebral ventricles, 
etc. 
 
іі) Second order targeting 
It involves delivery of drug to special cells such as tumor cells or kupffer cells 
in lives. 
 
ііі) Third order targeting  
Third order targeting is essential for gene delivery and exogenous DNA to the 
nucleus. Targeting is based on the structure with in a cell.  The active targeting more 
specific for kupffer cells of the liver and parenchymal cells like hepatocytes.  
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Dual Targeting 
In this targeting approach carrier molecule itself have their own therapeutic 
activity and thus increase the therapeutic effect of drug. For example, a carrier 
molecule having its own antiviral activity can be loaded with antiviral drug and the 
net synergistic effect of drug conjugate was observed. 
 
Double Targeting  
When temporal and spatial methodologies are combined to target a carrier 
system, then targeting may be called double targeting. Spatial placement relates to 
targeting drugs to specific organs. 
 
Combination targeting 
Combination targeting is for site specific delivery of proteins and peptides. 
The targeting systems are equipped with carrier and polymer. This method is more 
specific for gene therapy.    
 
1.1.3. Drug delivery carriers 4,9 
Carriers are used to achieve targeted drug delivery. Carrier is one of the 
special molecule or system essentially required for effective transportation of loaded 
drug up to the preselected sites. They are engineered vectors, which retain drug inside 
or onto them either via encapsulation and/ or via spacer moiety and transport or 
deliver it into vicinity of target cell. 
  
Some carrier based drug delivery systems are, 
¾ Microspheres and micro capsules 
¾ Nanoparticles 
¾ Monoclonal antibodies 
¾ Prodrugs 
¾ Resealed erythrocytes 
¾ Artificial cells 
¾ Neutrophils  
¾ Vesicular carriers 
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1.1.4. Vesicular system – carrier for drug delivery 5 
Vesicles act as the vehicle of choice in drug delivery. Lipid vesicles were 
found to be of value in immunology, membrane biology, diagnostic techniques, and 
most recently, genetic engineering. Vesicles can play a major role in modelling 
biological membranes, and in the transport and targeting of active agents. Vesicular 
drug delivery system has some of the advantages, 
 
¾  Like other targeted drug delivery systems, it prolongs the existence of the drug 
in systemic circulation, and perhaps, reduces the toxicity due to the delivery of 
drug directly to the site of infection. 
¾ Both hydrophilic and lipophilic drugs can be incorporated. 
¾ Delays elimination of rapidly metabolizable drugs and thus function as 
sustained release systems. 
Some important vesicular drug delivery systems are, 
¾ Liposomes 
¾ Sphinosomes  
¾ Transferosomes   
¾ Pharmacosomes 
¾ Niosomes 
 
і) Liposomes  
Liposomes are simple microscopic vesicles in which lipid bilayer structures 
are present with an aqueous volume entirely enclosed by a membrane, composed of 
lipid molecule. There are a number of components present in liposomes, with 
phospholipid and cholesterol being the main ingredients. The type of phospholipids 
includes phosphoglycerides and sphingolipids, and together with their hydrolysis 
products. 
 
іі) Sphinosomes  
Liposome has some stability problems. Liposomal phospholipid can undergo 
chemical degradation such as oxidation and hydrolysis. The hydrolysis may be 
avoided altogether by use of lipid which contains ether or amide linkage instead of 
ester linkage (such are found in sphingolipid) or phospholipid derivatives with the 2- 
ester linkage replaced by carbomoyloxy function. Thus sphingolipid are been 
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nowadays used for the preparation of stable liposomes known as sphingosomes. 
Sphingosome may be defined as “concentric, bilayered vesicle in which an aqueous 
volume is entirely enclosed by a membranous lipid bilayer mainly composed of 
natural or synthetic sphingolipid. 
 
ііі) Transferosomes  
Transferosomes  was introduced for the effective transdermal delivery of 
number of low and high molecular weight drugs.It consist of both hydrophilic and 
hydrophobic properties,high deformablity gives better penetration of intact vescicles. 
A transferosomes, in functional terms, may be described as lipid droplets of such 
deformability that permits its easy penetration through the pores much smaller than 
the droplets size. They protect the encapsulated drug from metabolic degradation. In 
thermodynamics terms this typically corresponds to an aggregate in the quasi-
metastable state, which facilitates the formation of highly curved bilayers.  
 
іv) Pharmacosomes 
The term pharmacosome comprises of two main parts - Pharmacon (active 
principle) and some carriers (Goymann and Hamann, 1991) Vaizogle and Speiser 
(1986) postulated that amphipathic drug can self assemble to form vesicle and these 
vesicles are termed as pharmacosomes. Drug covalently bound to lipid may exist in a 
colloidal dispersion as ultrafine, micelles or hexagonal aggregates which are known as 
pharmacosomes. 
 
v) Niosomes 
Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures 
formed on admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether 
class and cholesterol with subsequent hydration in aqueous media. Niosomes are 
promising vehicle for drug delivery and being non-ionic, Niosomes are unilamellar or 
multilamellar vesicles formed from synthetic non-ionic surfactants. They are very 
similar to the liposomes. Niosomal drug delivery is potentially applicable to many 
pharmacological agents for their action against various diseases. Niosomes have 
shown promise in the release studies and serve as a better option for drug delivery 
system. The drug is incorporated into niosomes for a better targeting of the drug at 
appropriate tissue destination. 
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1.2 Salient features of niosomes 7 
• Niosomes act as alternatives of liposomes. Disadvantages in the liposomes are 
avoided in this. 
• Osmotically active and stable. 
• Niosome increases the stability of entrapped drug. 
• They can be made to reach the site of action by oral, parenteral as well as 
topical routes. 
• Surfactant used in niosome does not require special conditions. 
• Surfactants used in niosomes are biodegrable, biocompatible and non-
immunogenic. 
• They improve the therapeutic performance of the drug molecules by delayed 
clearance from the circulation. 
• Niosome exhibit flexibility in their structural characteristics (composition, 
fluidity, size) and can be designed to desired situation. 
 
1.3. Composition of niosomes 10 
Niosomes contain two major component, Cholesterol and Nonionic 
surfactants.  Cholesterol is used to provide rigidity and proper shape to the niosomes. 
surfactants play a major role in the formation of niosomes. The following non-ionic 
surfactants are generally used for the preparation of niosomes the spans 
(span60,40,20,85,80), tweens (tween 20,40,60,80) and brijs (brij 30,35,52,58,72,76). 
The non ionic surfactants possess a hydrophillic head and a hydrophobic tail.  
 
 
Fig:1 Internal structure of niosome 
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1.4. Surfactants used in formulation of niosomes 10 
Niosomes are non-ionic surfactant unilamellar or multilamellar vesicles 
formed from synthetic non-ionic surfactants. The surfactants that are reported to form 
niosomes are as follows: 
 
1. Ether linked surfactant 
These are surfactants in which the hydrophilic hydrophobic moieties are ether 
linked, polyoxyethylene alkyl ethers with the general formula (CnEOm), where n; i.e. 
number of carbon atoms varies between 12 and 18 and m; i.e. number of oxyethylene 
unit varies between 3 and 7. 
 
2. Di-alkyl chain surfactant 
Surfactant was used as a principal component of niosomal preparation of 
stibogluconate and its potential in delivering sodium stibogluconate in experimental 
marine visceral leishmaniasis has been explored. 
 
                                                      C16H33CH-O [-CH2-CH-O]7-H 
                                                      | | 
                                                      CH2 CHOH 
                                                       | 
                                                      C 12H 25-O (mol. Wt. 972) 
 
3. Ester linked 
These are the surfactants in which hydrophilic and hydrophobic moieties are 
ester linked. Ester linked surfactant, 
 
                                                      C15 H31 CO [O-CH2-CH-CH]2-OH 
                                                       | 
                                                      OH (mol. Wt. 393) 
 
This surfactant was also studied for its use in the preparation of stibogluconate 
bearing niosomes and in delivery of sodium stibogluconate to the experimental 
marine visceral leishmaniasis following administration of niosomal system. The 
commercial sorbitan esters are H-C-OH mixtures of the partial esters of sorbital. 
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4. Sorbitan Esters: 
The typical structural formula of sorbitan ester is, 
 
                                                                CH2 (where, R is H or an alkyl chain) 
                                                                 | 
                                                           H-C-OH 
                                                                 | 
                                                  RCOO- C-H 
                                                                 | 
                                                            H-C-OH 
                                                                 | 
                                                           H-C-OOC-R 
                                                                 | 
                                                   CH2OOC-R 
 
The formula of a representative component is shown above. Sorbitan esters 
based niosomes bearing methotrexate were prepared and evaluated for 
pharmacokinetics of the entrapped methotrexate in tumor bearing mice. 
 
5. Poly-sorbates 
The typical structural formula of polysorbates is 
- 
                                                                CH2 
                                                                 | 
                                                            H-C-O (CH2-CH2-O) H 
                                                                 | 
                                       (OCH-CH2)-O-C-H 
                                                                 | 
                                                           H-C-O-(CH2-CH2-O)y H 
                                                                 | 
               CH2-O (CH2-CH2-O) z OCR 
 
When n = x + y + z + 2 and R is an alkyl chain this series of surfactants has 
been used to study the pharmacokinetics of niosomal entrapped methotrexate. 
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1.5. Types of niosomes 
1. Small unilamellar vesicles (SUV) 
SUV are commonly produced by sonication, and French Press procedures. 
Ultrasonic electro capillary emulsification or solvent dilution techniques can be used 
to prepare SUVs. (size -0.025-0.05 μm) 
 
2. Multilamellar vesicles (MUV)  
Exhibit increased-trapped volume and equilibrium solute distribution, and 
require hand-shaking method. They show variations in lipid compositions. (size > 
0.05 μm)   
 
3. Large unilamellar vesicles (LUV) 
The injections of lipids solubilised in an organic solvent into an aqueous 
buffer, can result in spontaneous formation of LUV, but the better method of 
preparation of LUV is Reverse phase evaporation, or by Detergent solubilisation 
method. (size > 0.10 μm). 
 
1.6. Advantages of niosomes 5,7,8 
• Niosomal vesicle suspension is water–based vehicle. This offers high patient 
compliance in comparison with oily dosage forms. 
• They possess an infrastructure consisting of hydrophilic, amphiphilic and 
lipophilic moieties together and as a result can accommodate drug molecules 
with a wide range of solubilities. 
• The characteristics of the vesicle formulation are variable and controllable. 
Altering vesicle composition, size, lamellarity, tapped volume, surface charge 
and concentration can control the vesicle characteristics. 
• The vesicles may act as a depot, releasing the drug in a controlled manner. 
• They improve oral bioavailability of poorly absorbed drugs and enhance skin 
penetration of drugs. 
• They can be made to reach the site of action by oral, parenteral as well as 
topical routes 
• They improve the therapeutic performance of the drug molecules by delayed 
clearance from the circulation, protecting the drug from biological environment 
and restricting effects to target cells. 
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• Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous 
phase to regulate the delivery rate of drug and administer normal vesicle in 
external non-aqueos phase. 
                                                              
1.7. Factors affecting formation of niosomes 11,12   
і) Nature of surfactants 
Surfactants used for preparation of niosomes must contain a hydrophilic head 
and hydrophobic tail. The hydrophobic tail may consist of one or two alkyl or 
perfluoroalkyl groups or in some cases a single steroidal group. The ether type 
surfactants with single chain alkyl as hydrophobic tail is more toxic than 
corresponding dialkylether chain. The ester type surfactants are chemically less stable 
than ether type surfactants and the former is less toxic than the latter due to ester-
linked surfactant degraded by esterases to triglycerides and fatty acid in vivo. The 
surfactants with alkyl chain length from C12-C18 are suitable for preparation of 
niosome. 
 
іі) Structure of surfactants 
The geometry of vesicle to be formed from surfactants is affected by its 
structure, which is related to critical packing parameters. On the basis of critical 
packing parameters of surfactants can predicate geometry of vesicle to be formed. 
Critical packing parameters can be defined using following equation,  
       v 
CPP (Critical Packing Parameters) = 
    lc × a0 
 
Where v = hydrophobic group volume, 
lc = the critical hydrophobic group length, 
a0 = the area of hydrophilic head group. 
 
From the critical packing parameter value type of miceller structure formed can be 
ascertained as given below, 
 
If CPP < ½ then formation of spherical micelles, 
If ½ < CPP < 1 formation of bilayer micelles, 
If CPP > 1 formation of inverted micelles. 
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ііі) Membrane composition 
The stable niosomes can be prepared with addition of different additives along 
with surfactants and drugs. Niosomes formed have a number of morphologies and 
their permeability and stability properties can be altered by manipulating membrane 
characteristics by different additives. 
 
іv) Nature of encapsulated drug 
The physico-chemical properties of encapsulated drug influence charge and 
rigidity of the niosome bilayer. The drug interacts with surfactant head groups and 
develops the charge that creates mutual repulsion between surfactant bilayers and 
hence increases vesicle size. 
 
v) Temperature of hydration 
Hydration temperature influences the shape and size of the niosome. For ideal 
condition it should be above the gel to liquid phase transition temperature of system. 
Temperature change of niosomal system affects assembly of surfactants into vesicles 
and also induces vesicle shape transformation. 
 
1.8. Characterization of niosomes 12,15 
і) Size 
Shape of niosome vesicles assumed to be spherical, their mean diameter can 
be determined by using laser light scattering method. Also diameter can be 
determined by using electron microscopy, molecular sieve chromatography, 
ultracentrifugation, photon correlation microscopy and optical microscopy. 
 
іі) Bilayer formation 
 Assembly of non-ionic surfactants to form bilayer vesicle is characterized by 
X-cross formation under light polarization microscopy. 
 
ііі) Number of lamellae 
It can be determined by using NMR spectroscopy, small angle X-ray 
scattering and electron microscopy. 
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іv) Membrane rigidity 
Membrane rigidity can be measured by means of mobility of fluorescence 
probe as function of temperature. 
 
v) Entrapment efficiency (EE) 
The entrapment efficiency (EE) is expressed as 
                
             Amount entrapped 
EE =                                         × 100 
            Total amount added 
 
It is determined after separation of unentrapped drug, on complete vesicle 
disruption by using about 1ml of 2.5% sodium lauryl sulfate, briefly homogenized and 
centrifuged and supernatant assayed for drug after suitable dilution. Entrapment 
efficiency is affected by following factors. 
 
a) Surfactants 
The chain length and hydrophilic head of non-ionic surfactants affect 
entrapment efficiency, such as stearyl chain C18 non-ionic surfactant vesicles show 
higher entrapment efficiency than lauryl chain C12 non-ionic surfactant vesicles. The 
tween series surfactants bearing a long alkyl chain and a large hydrophilic moiety in 
the combination with cholesterol at 1:1 ratio have highest entrapment efficiency for 
water soluble drugs. HLB value of surfactants affects entrapment efficiency, such as 
HLB value of 14 to 17 is not suitable for niosomes, but HLB value of 8.6 has highest 
entrapment efficiency and entrapment efficiency decreases with decrease in HLB 
value from 8.6 to 1.7. The entrapment efficiency is affected by phase transition 
temperature of surfactants, i.e. span 60 exhibits highest entrapment efficiency in series 
having highest transition temperature (Tc). 
 
b) Cholesterol contents 
The incorporation of cholesterol into bilayer composition of niosome induces 
membrane-stabilizing activity and decreases the leakiness of membrane. Hence, 
incorporation of cholesterol into bilayer increases entrapment efficiency.  
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1.9. Comparision of niosome with liposome 6,8  
Niosomes are now widely studied as alternative to liposomes. Liposomes face 
problems such as, they are expensive, their ingredients like phospholipids are 
chemically unstable because of their predisposition to oxidative degradation, they 
require special storage and handling and purity of natural phospholipids is variable. 
Niosomes do not have any of these problems. Also since niosomes are made of 
uncharged single-chain surfactant molecules as compared to the liposomes which are 
made from neutral or charged double chained phospholipids, the structure of 
niosomes is different from that of liposomes. However Niosomes are similar to 
liposomes in functionality. Niosomes also increase the bioavailability of the drug and 
reduce the clearance like liposomes. Niosomes can also be used for targeted drug 
delivery, similar to liposomes. 
 
 
Table:2 
Carrier 
System 
Size 
Range Features 
Method of 
Preparation Application 
Liposomes 25nm- 
100μm 
microscopic 
vesicles 
composed 
of one or more 
concentric lipid 
bilayers, 
separated 
by water or 
aqueous 
buffer 
compartment 
Mechanical 
Dispersion. 
solvent 
dispersion 
detergent 
removal etc. 
In cancer, 
malaria, AIDS, 
lung therapies. 
As 
radio diagnostic 
carrier. 
As an 
immunological 
adjuvant. 
Niosomes 10 to       
1000 nm 
 
non-ionic 
surfactant 
vesicles 
are bilayered 
structures 
 
Ether injection, 
Sonication, 
REV, 
microfluidization 
etc. 
Targeting of 
bioactive 
agents 
Delivery of 
peptide drug 
In diseases 
like neoplasia, 
leishmaniasis 
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 1.10. Methods of preparation of niosomes 8,14,15 
 
і) Ether injection method  
This method provides a means of making niosomes by slowly introducing a 
solution of surfactant dissolved in diethyl ether (volatile organic solvent) into warm 
water maintained at 60°C. The surfactant mixture in ether is injected through 14- 
gauge needle into an aqueous solution of material. Vaporization of ether (volatile 
organic solvent) leads to formation of single layered vesicles. Depending upon the 
conditions used the diameter of the vesicle range from 50 to 1000 nm. 
 
 
Fig:2 Ether injection method 
 
іі) Thin film hydration technique 
 The mixture of vesicles forming ingredients like surfactant and cholesterol are 
dissolved in a volatile organic solvent (diethyl ether, chloroform or methanol) in a 
round bottom flask. The organic solvent is removed at room temperature (20°C) using 
rotary evaporator leaving a thin layer of solid mixture deposited on the wall of the 
flask. The dried surfactant film can be rehydrated with aqueous phase at 0-60°C with 
gentle agitation. This process forms typical multilamellar niosomes. 
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removed at 40°C under low pressure. The resulting viscous niosome suspension is 
diluted with PBS and heated on a water bath at 60°C for 10 min to yield niosomes. 
 
v) Micro fluidization  
It is a recent technique used to prepare unilamellar vesicles of defined size 
distribution. This method is based on submerged jet principle in which two fluidized 
streams interact at ultra high velocities, in precisely defined micro channels within the 
interaction chamber. The impingement of thin liquid sheet along a common front is 
arranged such that the energy supplied to the system remains within the area of 
niosomes formation. The result is a smaller size, greater uniformity and better 
reproducibility of niosomes formed. 
 
 
Fig:5 Micro fluidization 
 
vі) Multiple membrane extrusion method  
Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform is made 
into thin film by evaporation. The film is hydrated with aqueous drug polycarbonate 
membranes, solution and the resultant suspension extruded through which are placed 
in series for upto 8 passages. It is a good method for controlling niosome size. 
 
vіі) Trans membrane pH gradient (inside acidic) Drug Uptake Process (remote 
Loading) 
Surfactant and cholesterol are dissolved in chloroform. The solvent is then 
evaporated under reduced pressure to get a thin film on the wall of the round bottom 
flask. The film is hydrated with 300 µM citric acid (pH 4.0) by vortex mixing. The 
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multilamellar vesicles are frozen and thawed 3 times and later sonicated. To this 
niosomal suspension, aqueous solution containing 10 mg/ml of drug is added and 
vortexed. The pH of the sample is then raised to 7.0-7.2 with 1M disodium phosphate. 
This mixture is later heated at 60°C for 10 minutes to give niosomes.  
 
vііі) The “Bubble” Method 
It is novel technique for the one step preparation of liposomes and niosomes 
without the use of organic solvents. The bubbling unit consists of round-bottomed 
flask with three necks positioned in water bath to control the temperature. Water-
cooled reflux and thermometer is positioned in the first and second neck and nitrogen 
supply through the third neck. Cholesterol and surfactant are dispersed together in this 
buffer (pH 7.4) at 70°C, the dispersion mixed for 15 seconds with high shear 
homogenizer and immediately afterwards “bubbled” at 70°C using nitrogen gas. 
 
іx) Formation of niosomes from proniosomes 
Another method of producing niosomes is to coat a water-soluble carrier such 
as sorbitol with surfactant. The result of the coating process is a dry formulation. In 
which each water-soluble particle is covered with a thin film of dry surfactant. This 
preparation is termed as Proniosomes. The niosomes are recognized by the addition of 
aqueous phase at T > Tm and brief agitation. T=Temperature. Tm = mean phase 
transition temperature. 
 
 
 
 
Fig:6 Formation of niosomes from proniosomes 
 
1.11. Methods of separation of unentrapped drug from niosomes 8,11  
The removal of unentrapped solute from the vesicles can be done by various 
techniques, which include 
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і) Dialysis 
The aqueous niosomal dispersion is dialyzed in dialysis tubing against suitable 
dissolution medium at room temperature. The samples are withdrawn from the 
medium at suitable time intervals, centrifuged and analysed for drug content using 
suitable method (U.V spectroscopy, HPLC etc). 
 
іі) Gel Filtration 
The unentrapped drug is removed by gel filtration of niosomal dispersion 
through a Sephadex- G-50 column and eluted with suitable mobile phase and 
analyzed with suitable analytical techniques. 
 
ііі) Centrifugation 
The niosomal suspension is centrifuged and the supernatant is separated. The 
pellet is washed and then resuspended to obtain a niosomal suspension free from 
unentrapped drug. 
 
1.12. Stability of niosomes 1 
Physical stability  
The niosomes can change their physical characteristics in several ways.  
¾ The particle size may change because of aggregate formation and fusion.  
¾ Occurrence of phase separation of bilayer components, upon storage.  
¾ Leakage of encapsulated material from niosomes.  
 
The changes in particle upon storage of phosphatidyl choline containing 
niosomes over pharmaceutically relevant time intervals can be minimized by the 
selection of proper charge inducing agents. Mostly, negatively charged phospholipids 
(phosphatidyl glycerol) are used to stabilize the niosomes.  
 
The permeability of bilayers is highly dependent on the physico-chemical 
properties of the bilayer, drug and the temperature. Three categories of drugs can be 
discerned.  
 
¾ Highly hydrophilic, non-bilayer interacting drugs.  
¾ Drugs with some lipophilicity.  
¾ Strongly lipophilic drugs.  
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In category first, the presence of cholesterol in the bilayer of the egg 
phosphatidyl choline niosomes dramatically reduces the permeability. For gel state 
bilayers, permeability is low with or without cholesterol. It is clear that if in vivo 
performance allows ‘gel state’ bilayers to be used, the shelf life of the niosomes in 
aqueous media with the proper pH might easily meet industrial demands. In the 
second category, the drug tends to be difficult to keep entrapped over periods of 
months as long as outside sink conditions prevail. In the third category, strongly 
lipophilic drugs have high affinity for the bilayer and therefore these drugs stay there 
over a long period of time, independently of the state of the bilayer. 
 
As the final remark, the presence of hydrolysis or oxidation reduction products 
can affect bilayer properties. Although, lysophosphatidyl choline is known to be a 
lipid bilayer solubilizer, the solubilizing effect of lysophosphatidyl choline in 
degrading niosomes is neutralized by the simultaneous appearance of fatty acids in the 
bilayer.  
 
The niosomes stored in freeze dried form is preferred for proper in vivo 
performance of niosomes with long term stability. To maintain the particle size 
distribution after freeze drying-rehydration cycle, a cryoprotectant needs to be added. 
Usually sugars are used as cryoprotectant. 
 
¾ The formation of amorphous glass structures during the freeze drying process 
may avoid mechanical damage inflected by ice crystals. It is recommended to 
store these cakes below the glass transition temperature.  
¾ The sugars may interact with the polar head groups of the phospholipids and 
stabilize the membranes when the bilayer stabilizing water is removed by 
sublimation.  
 
Chemical stability 
The stability of niosomes depends on the chemical stability of the lipid 
components and the bilayer components of niosomes, designed for carrying a drug or 
phospholipids. Usually, hydrolysis and peroxidation are the two degradation process 
which occurs with phospholipids. Apart from pH, other experimental conditions like 
temperature, ionic strength, buffer species, and ultra sonication were reported to 
influence hydrolysis reactions. Many investigators choose the formation of 
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lysophosphatidyl choline as a standard measure for the chemical stability to 
phospholipids. Since, the presence of lysophosphatidyl choline in lipid bilayer greatly 
enhances the permeability of niosomes, the most important method for minimizing 
this problem is the proper sourcing of the phospholipid to be used. They should be 
essentially free from any lyso-phosphatidyl choline to start with and free of any 
peroxidation of phospholipids produces the formation of cyclic peroxides and hydro 
peroxides. Peroxidation of the phospholipids may be minimized by a number of ways 
such as, 
 
¾ Minimum use of unsaturated phospholipids.  
¾ Use of nitrogen or argon to minimize exposure to oxygen.  
¾ Use of light resistant container.  
¾ Removal of heavy metals (EDTA).  
 
Stability in biological fluids  
The inability of niosomes to retain entrapped substances when incubated in 
blood or plasma has been known for a decade. The instability of niosomes in plasma 
appears to be the result of transfer of bilayer lipids to albumin and high density 
lipoproteins. Both lecithin and cholesterol also exchanges with the membrane of red 
blood corpuscle. Niosomes are most susceptible to high density lipoprotein attack at 
their gel to liquid crystalline phase transition temperature. The susceptibility of 
niosomal phospholipids to lipoprotein and phospholipase attack is strongly dependent 
on niosome size and type. Generally, multilamellar vesicles are most stable whereas 
small lamellar vesicles are least stable. The bile salts also destabilize the bilayer 
membrane structure, thereby, leading to release of the entrapped material. 
 
1.13. Application of niosomes 13,15,16 
Drug targeting 
One of the most useful aspects of niosomes is their ability to target drugs. 
Niosomes can be used to target drugs to the reticulo-endothelial system. The reticulo-
endothelial system (RES) preferentially takes up niosome vesicles. The uptake of 
niosomes is controlled by circulating serum factors called opsonins. These opsonins 
mark the niosome for clearance. Such localization of drugs is utilized to treat tumors 
in animals known to metastasize to the liver and spleen. This localization of drugs can 
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also be used for treating parasitic infections of the liver. Niosomes can also be utilized 
for targeting drugs to organs other than the RES. A carrier system (such as antibodies) 
can be attached to niosomes (as immunoglobulins bind readily to the lipid surface of 
the niosome) to target them to specific organs. Many cells also possess the intrinsic 
ability recognize and bind specific carbohydrate determinants, and this can be 
exploited by niosomes to direct carrier system to particular cells. 
 
Anti-neoplastic Treatment  
Most antineoplastic drugs cause severe side effects. Niosomes can alter the 
metabolism; prolong circulation and half life of the drug, thus decreasing the side 
effects of the drugs. Niosomal entrapment of Doxorubicin and Methotrexate (in two 
separate studies) showed beneficial effects over the unentrapped drugs, such as 
decreased rate of proliferation of the tumor and higher plasma levels accompanied by 
slower elimination. 
 
Leishmaniasis  
Leishmaniasis is a disease in which a parasite of the genus Leishmania invades 
the cells of the liver and spleen. Commonly prescribed drugs for the treatment are 
derivatives of antimony (antimonials), which in higher concentrations can cause 
cardiac, liver and kidney damage. Use of niosomes in tests conducted showed that it 
was possible to administer higher levels of the drug without the triggering of the side 
effects, and thus allowed greater efficacy in treatment. 
 
Delivery of Peptide Drugs: 
Oral peptide drug delivery has long been faced with a challenge of bypassing 
the enzymes which would breakdown the peptide. Use of niosomes to successfully 
protect the peptides from gastrointestinal peptide breakdown is being investigated. In 
an invitro study conducted by Yoshida et al, oral delivery of a vasopressin derivative 
entrapped in niosomes showed that entrapment of the drug significantly increased the 
stability of the peptide. 
 
Use in Studying Immune Response: 
Due to their immunological selectivity, low toxicity and greater stability; 
niosomes are being used to study the nature of the immune response provoked by 
antigens. 
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Niosomes as Carriers for Haemoglobin: 
Niosomes can be used as carriers for haemoglobin within the blood. The 
niosomal vesicle is permeable to oxygen and hence can act as a carrier for 
haemoglobin in anemic patients. 
 
Transdermal Drug Delivery Systems Utilizing Niosomes: 
One of the most useful aspects of niosomes is that they greatly enhance the 
uptake of drugs through the skin. Transdermal drug delivery utilizing niosomal 
technology is widely used in cosmetics; in fact, it was one of the first uses of the 
niosomes. Topical use of niosome entrapped antibiotics to treat acne is done. The 
penetration of the drugs through the skin is greatly increased as compared to un-
entrapped drug. Recently, transdermal vaccines utilizing niosomal technology is also 
being researched. A study conducted by P. N. Gupta et al has shown that niosomes 
(along with liposomes and transfersomes) can be utilized for topical immunization 
using tetanus toxoid. However, the current technology in niosomes allows only a 
weak immune response, and thus more research needs to be done in this field. 
 
Other Applications: 
a) Sustained Release: 
Azmin et al suggested the role of liver as a depot for methotrexate after 
niosomes are taken up by the liver cells. Sustained release action of niosomes can be 
applied to drugs with low therapeutic index and low water solubility since those could 
be maintained in the circulation via niosomal encapsulation. 
 
b) Localized Drug Action: 
Drug delivery through niosomes is one of the approaches to achieve localized 
drug action, since their size and low penetrability through epithelium and connective 
tissue keeps the drug localized at the site of administration. Localized drug action 
results in enhancement of efficacy of potency of the drug and at the same time 
reduces its systemic toxic effects e.g. Antimonials encapsulated within niosomes are 
taken up by mononuclear cells resulting in localization of drug, increase in potency 
and hence decrease both in dose and toxicity. The evolution of niosomal drug delivery 
technology is still at an infancy stage, but this type of drug delivery system has shown 
promise in cancer chemotherapy and anti-leishmanial therapy. 
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1.14. Disease overview 17  
HIV infection is caused by retroviruses. Retroviruses have an RNA genome 
and the unique property of transcribing a DNA of the RNA genome following 
penetration of the host cells. The DNA is then used as a template to transcribe new 
RNA Viral copies – thus the term retrovirus. Retroviruses generally evade host 
immune responses, and cause persistent infection in several species. HIV has a core 
consisting of the RNA genome and core protein surrounded by an envelope with high 
lipid content rendering it sensitive to organic solvents. 
 
The unique feature of the virus is that it gains entry to host cells by binding to 
the CD4 receptor using the viral surface membrane glycoprotein 120. This allows 
viral attachment and penetration of the host cells. The CD4 receptor is present 
predominantly on T- helper lymphocytes, which are therefore a major target for the 
virus. Following penetration of the host cells, the viral RNA is transcribed by the viral 
enzyme reverse transcriptase into a DNA copy which incorporated into the host cell 
genomic DNA. This viral DNA may then lie dormant within the cell or undergo 
replication resulting in transcription of RNA copies and translation to virus proteins 
resulting in new virus formation and assembly. Viruses then bud from the cell surface. 
New virus is then available to infect other cells and repeat the process. 
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2. LITERATURE REVIEW 
Kandasamy Ruckmani18 et al., (2010), prepared and optimized Zidovudine 
niosomes by altering the proportions of tween, span and cholesterol. The effect of 
process related variables like sonication time, hydration time, rotation speed of 
evaporation flask and effect of charge inducing agent was evaluated. Zidovudine 
niosomes formulated with tween 80 entrapped high amounts of drug and the addition 
of dicetyl phosphate enhanced the drug release for longer time. The mechanism of 
release from tween 80 formulation was the Fickian type and obeyed first order release 
kinetics.   
Donatella Paolino19 et al., (2008), prepared an innovative niosomal system made up 
of α,ω-hexadecyl bis-(1-aza-18-crown-6) (Bola), Span 80 and cholesterol (2:5:2 molar 
ratio). It was proposed as a topical delivery system for 5-fluorouracil (5-FU), largely 
used in the treatment of different forms of skin cancers. Bola-niosomes showed a 
mean size of 400 nm, which were reduced to 200 nm by a sonication procedure with a 
polydispersion index value of 0.1. Bolaniosomes showed a loading capacity of 40% 
with respect to the amount of 5-FU added during the preparation. 5-FU-loaded bola 
niosomes showed an improvement of the cytotoxic effect with respect to the free 
drug. Confocal laser scanning microscopy studies were carried out to evaluate both 
the extent and the time-dependent bola-niosome–cell interaction. Bola-niosomes 
provided an increase of the drug penetration of 8- and 4-folds with respect to a drug 
aqueous solution and to a mixture of empty bola-niosomes with a drug aqueous 
solution.  
 
Mahmoud Mokhtar20 et al., (2008), prepared niosomes from proniosomal gels. 
Flurbiprofen niosomes were developed using span 20 (Sp 20), span 40 (Sp 40), span 
60 (Sp 60), and span 80 (Sp 80) without and with cholesterol. The influence of 
different processing and formulation variables such as surfactant chain length, 
cholesterol content, drug concentration, total lipid concentration, negatively or 
positively charging lipids, and the pH of the dispersion medium on flurbiprofen EE% 
was demonstrated. Also, the release of the prepared niosomes in phosphate buffer (pH 
7.4) was illustrated. Results indicated that the EE% followed the trend Sp 60 
(C18)>Sp 40 (C16)>Sp 20 (C12)>Sp 80 (C18). Cholesterol increased or decreased the 
EE% depending on either the type of the surfactant or its concentration within the 
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formulae. Invitro release study shows increase in cholesterol amounts into niosomal 
formulations could increase the release of flurbiprofen. 
 
Inas A. Darwish21 et al., (1997) formulated niosomes with 1:1 molar ratio of N-
palmitoyl-2 -aminomethyl-15 -crown-5 (PCE) and cholesterol (CHOL) with and 
without the addition of 10 mol% Solulan C24 (poly-24-oxyethylene cholesteryl 
ether). A water-soluble fluorescent marker, rhodamine B was encapsulated within 
these niosomes. Rhodamine B containing PCE/CHOL niosomes of approximately 6.3 
mm diameter were visualised by optical microscopy  and  sonicated  PCE/CHOL  
niosomes  of  approximately  134 nm  in  size  were visualised by transmission 
electron microscopy. The release of the fluorescent marker rhodamine B from 
PCE/CHOL niosomes was slightly increased by the addition of calcium ions but 
remained unaffected by the addition of sodium ions. 
 
Varaporn Buraphacheep Junyaprasert22 et al., (2008) investigated the influence of 
different types of membrane additives including negative charge (dicetylphosphate, 
DCP), positive charge (stearylamine, STR) and non-ionic molecule (cholesteryl poly-
24-oxyethylene ether, SC24) on the physicochemical properties of drug-free and 
drug-loaded niosomes. Salicylic acid having different proportions of ionized and 
unionized species at different pH was selected as a model drug. The results shows 
addition of the membrane additives changed the zeta potential depending on the type 
of the additives.The particle sizes of all developed niosomes were between 217 to 360 
nm. The entrapment efficiency (%E.E.) of all salicylic acid niosomes at pH 3 was 
higher than that of niosomes at pH 5. After 3 months of storage at 4°C, the particle 
size of the niosomes remained in the nanosize range except for DCP salicylic acid 
niosomes at pH 3 whose size increased due to instability of DCP at low pH.  All 
niosomes showed no leakage of the salicylic acid after 3 months of storage indicating 
the good stability. 
 
P. Arunothayanun23 et al., (2000) prepared two niosomal systems based on a 
hexadecyl diglycerol ether (C16G2), cholesterol and poly-24-oxyethylene cholesteryl 
ether (Solulan C24) in the molar ratios 91:0:9 and 49:49:2 were prepared.  In this 
investigation, the effects of processing variables, particularly temperature and 
sonication, on the physical characteristics and phase transitional behaviour of two 
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niosomal systems based on a hexadecyl diglycerol ether (C16G2) have been studied. 
Entrapment of 5(6)-carboxyfluorescein, particle size and morphology were examined. 
the polyhedral systems containing C16G2 and Solulan C24 were found to have a 
larger particle size and higher carboxyfluorescein entrapment efficiency. 
 
Prabagar Balakrishnan24 et al., (2009) reported minoxidil niosomes for enhanced 
skin delivery and niosomes efficiency, particle size, zeta suggest that these niosomal 
formulations could constitute a promising approach for topical delivery of Minoxidil 
in  hair loss treatment as a possible potential and stability. Skin permeation studies 
were performed using   static vertical diffusion franz cells hairless mouse skin and the 
results approach to improve the low skin penetration and bioavailability shown by 
conventional topical vehicle for minoxidil niosomes using characteristics thin film 
hydration method. The result suggests that these niosomal formulations have greater 
potential for drug cutaneous targeting and could be used as a feasible cargo carrier for 
the topical delivery of  minoxidil in skin diseases such as hair loss. 
 
Aranya Manosroi25 et al., (2008), formulated niosome encapsulated D- (+) -glucose 
by using a novel supercritical carbon dioxide fluid (scCO2) technique. Niosomes were 
composed of Tween61/cholesterol at 1:0, 3:1, 1:1, 1:3 and 0:1 molar ratios and  
entrapped with  D -(+) glucose by the scCO2 method without and with ethanol, and 
the conventional chloroform film method with sonication. Tween61/cholesterol at 1:1 
molar ratio niosomes prepared by all methods exhibited the best physical stability. 
Niosomes by the scCO2 method with 10% (w/w) ethanol gave higher entrapment 
efficiency (12.22±0.26%) than those by the conventional chloroform film method 
with sonication (10.85±0.24%) and the scCO2 method without ethanol (8.40±1.60%).  
 
Ahmed S. Guinedi26 et al., (2005), reported as niosome is a novel approach to 
improve the low corneal penetration and bioavailability characteristics shown by 
conventional ophthalmic vehicles. Niosomes formed from Span 40 or Span 60 and 
cholesterol in the molar ratios of 7:4, 7:6 and 7:7 were prepared using reverse-phase 
evaporation and thin film hydration methods. The prepared systems were 
characterized for entrapment efficiency, size, shape and in vitro drug release. Stability 
studies were carried out to investigate the leaching of drug from niosomes during 
storage. The results showed that the type of surfactant, cholesterol content and the 
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method of preparation altered the entrapment efficiency and drug release rate from 
niosomes. Higher entrapment efficiency was obtained with multilamellar niosomes 
prepared from Span 60 and cholesterol in a 7:6 molar ratio. Niosomal formulations 
have shown a fairly high retention of acetazolamide inside the vesicles 
(approximately 75%) at a refrigerated temperature up to a period of 3 months.  
 
Parinya arunothayanun27 et al., (1999), formulated Luteinizing hormone releasing 
hormone (LHRH) loaded niosomes by various methods such as direct hydration at pH 
7.4.,  direct hydration at pH 3.0, dehydration-rehydration of vesicles (DRV),  
reversed-phase evaporation of vesicles, remote loading by (NH4)2SO4 gradient., and 
remote loading by pH gradient. In this higher level of entrapment is obtained in 
niosomes formulated by active loading methods. [i.e. (NH4)2SO4 gradient and pH 
gradient]. 
 
Sanyog Jain28 et al., (2005) developed mannosylated niosomes as a topical vaccine 
delivery carrier and adjuvant for the induction of both humoral and cellular immunity. 
Bovine serum albumin (BSA) - loaded niosomes composed of sorbitan 
monostearate/sorbitan trioleate (Span 60/Span 85), cholesterol and stearylamine as 
constitutive lipids were prepared by the reverse-phase evaporation method. The 
niosomes were coated with a modified polysaccharide O-palmitoyl mannan (OPM) to 
target them to Langerhan’s cells, the major antigen presenting cells found in 
abundance beneath the stratum corneum. Prepared niosomes were characterized in-
vitro for their size, shape, entrapment efficiency and ligand binding specificity. The 
serum IgG levels were significantly higher for the mannosylated niosomes as 
compared with plain uncoated niosomes. 
 
Zerrin sezgin bayindir29 et al., (2010), prepared Paclitaxel (PCT) loaded niosomes 
from the self-assembly of nonionic amphiphiles in aqueous media using different 
surfactants (Tween 20, 60, Span 20, 40, 60, Brij 76, 78, 72) by film hydration method. 
PCT was successfully entrapped in all of the formulations with encapsulation 
efficiencies ranging between 12.1-1.36% and 96.6-0.482%. PCT released from 
niosomes by a diffusion controlled mechanism. The slow release observed from these 
formulations might be beneficial for reducing the toxic side effects of PCT. 
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Depending on the addition of the negatively charged dicetyl phosphate to the 
formulations negative zeta potential values were obtained. 
 
Deepika Aggarwal30 et al., (2004), formulated niosomes to enhance the 
bioavailability of acetazolamide by the topical route and to improve the corneal 
permeability of the drug, niosomes of acetazolamide were prepared (employing span 
60 and cholesterol) by different methods. Niosomes were also prepared in the 
presence of dicetyl phosphate and stearylamine to obtain negatively and positively 
charged vesicles, respectively. It was found that the reverse - phase evaporation 
method gave the maximum drug entrapment efficiency (43.75%) as compared with 
ether injection (39.62%) and film hydration (31.43%) techniques. Drug entrapment 
efficiency varied with the charge and the percent entrapment efficiency for the REV 
method was 43.75, 51.23 and 36.26%for neutral, positively charged and negatively 
charged niosomes, respectively. 
 
E. O. Confalonieri31 et al., (2009) studied pharmacokinetic parameters of 
flurbiprofen (FBP) after intravenous (i.v.) administration (0.5 mg⁄ kg) of niosomal and 
nonniosomal formulations in dairy cattle. Niosomes of FBP showed a drug loading of 
92.0 ± 0.7% and the intravenous administration of the FBP niosomes to dairy cattle 
did not produce any immunological reaction associated to niosomal components. 
Niosomal FBP was slowly eliminated from plasma and mean residual time (MRT) 
and AUC0- t and t ½ values were significantly higher than those for non niosomal FBP 
formulations. The results presented in this study indicate that the long circulation of 
FBP niosomes offers a potential application for improving the pharmacokinetic 
parameters of short half-life drugs for clinical use. Niosomes offer new promising 
perspectives of drug delivery modules in bovine therapeutics. 
 
 Roopa Karki32 et al., (2008), studied niosomes as alternates to liposomes. An 
increasing number of non-ionic surfactant has been found to form vesicles, capable of 
entrapping hydrophilic and hydrophobic molecules. Isoniazid encapsulated as 
formulation using ethanol injection method. A different ratio of cholesterol was used. 
The formulated systems were characterised for in vitro by size distribution analysis, 
drug entrapment efficiency and drug release profiles. In vivo drug disposition was 
evaluated in normal, healthy albino rats for niosomal formulation. The size range 
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2.28±0.008 (plain Span 60), 2.311±0.009 (Span60: Cholesterol, 40:50), 2.15±0.002 
(Span60: Cholesterol 50:50). The entrapment release 74.12% (Plain Span 60), 80.23% 
(Span60: Cholesterol, 40:50), 76.26% (Span60: Cholesterol 50:50). In vitro release 
pattern indicated that about total drug content were released within 48 h. The 
niosomal drug delivery system has lesser toxicity than free drug. 
 
Minghuang Hong33 et al., (2009), repoted that the possibility of combination of the 
stealth action by polyethylene glycol cyanoacrylate-co-hexadecyl cyanoacrylate 
(PEG-PHDCA) modified niosomes and active targeting function of transferrin (Tf) by 
transferrin receptor-mediated endocytosis to promote drug delivery to solid tumor 
following intravenous administration with hydroxyl camptothecin (HCPT) as model 
drug. The HCPT loaded PEG-niosomes (PEG-NS) were prepared by thin-film 
hydration and ultrasound method; the periodate-oxidated Tf was coupled to terminal 
amino group of PEG to produce the active targeting vesicles with average diameters 
of 116 nm. The uptake of Tf-PEG-NS into KB cells was concentration and time 
dependent, which could be inhibited by low temperature and free Tf, indicating that 
the endocytosis process was energy-driven and receptor specific. Compared with 
HCPT injection, non-stealth niosomes and PEG-NS, Tf-PEG-NS demonstrated the 
strongest cytotoxicity to three carcinomatous cell lines (KB, K562 and S180 cells), 
the greatest intracellular uptake especially in nuclei, the highest tumor concentration 
and largest area under the intratumoral hydroxycamptothecin concentration curve, as 
well as the most powerful anti-tumor activity with the inhibition rate of 71% against 
S180 tumor in mice. The results showed that the transferring modified PEGylated 
niosomes could be one of the promising solutions to the delivery of anti-tumor drugs 
to tumor. 
 
Karthikeyan. D34 et al., (2009), prepared diclofenac sodium loaded niosomes by 
lipid film hydration method using span 60 and cholesterol with various molar ratios 
and characterized for invivo drug release study The molar ratio of 100:60 showed 
higher entrapment of drug and released 79.34 % ± 1.04 at10th h was used for the 
invivo drug release study. The molar ratio of 100:60 showed higher entrapment of 
drug and released 79.34 % ± 1.04 at 10th h was used for the invivo drug release study. 
The ocular irritation test of niosome containing diclofenac sodium was found to be 
safe which was confirmed by histopathological study. 
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R.A. Raja naresh 35 et al., (1996), prepared niosomes for targeting the delivery of 
anticancer drugs to the tumor site more quantitatively. In this direction attempts have 
been made to activate and exploit macrophages in delivering niosomal and 
thermosensitive niosomal bleomycin more quantitatively to tumor site using niosome 
encapsulated immunomodulators muramyl dipeptide and tuftsin. Niosomal bleomycin 
and thermosensitive niosomal bleomycin were prepared by lipid layer hydration 
method. The antitumor efficacy was assessed using two tumor models viz. Sarcoma-
180 and ehrlich ascites using Balb/C mice. Tumor distribution profiles of bleomycin 
before and after macrophage activation were studied in tumor bearing mice. The mean 
survival time of ehrlich ascites infected mice increased significantly after macrophage 
activation. Accumulation of higher bleomycin levels after macrophage activation 
exerted increased antitumor effect. The present study suggested that a more 
quantitative delivery of bleomycin encapsulated in niosomes, to the tumor site is 
possible after macrophage activation. 
 
Aliasgar36 et al., (2002), selected lipid film hydration technique to prepare niosomes 
containing nimesulide. The encapsulation of drug in niosome modified the bio 
distribution of drug in rats , which has shown higher and sustained plasma drug level 
profile compared to free drug solution. Prepared niosomes were analyzed for percent 
drug entrapment. The percent drug entrapment decreased (10.05% ± 0.008%) with 
decrease in HLB from 8.6 to 1.8 (Span 85). 
 
Pandya Hima37 et al., (2011), prepared and evaluated Trihexyphenidyl encapsulated 
niosomes by the thin film hydration method by using cholesterol and span 60 as a 
surfactant in different ratios. The formulation T2 (cholesterol:span40, 200:200) was 
showing the satisfactory particle size 4.6 ± 0.5 μm, entrapment efficiency 76.35 ± 
0.9% and in vitro drug release 78.8% for the extended period of time. So from the 
result we can conclude that the niosomes may be apromising carrier for 
Trihexyphenidyl and other drugs, especially due to their simple production and facile 
up. 
 
Shamsheer Ahmad S38 et al., (2011), formulated Lisinopril proniosomal gels by 
using Lecithin, Cholesterol as encapsulating agents, Surfactant, Span and permeation 
enhancers. The FTIR studies conducted revealed that there no interaction between 
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Lisinopril and excipients which. The physical characterization of proniosomal gels 
was found to be within the acceptable limits. It was observed that the gel formulations 
showed good spreadability and viscosity. Determination of vesicle size was found to 
be 20.10-26.23μm. The proniosomes showed spherical and homogenous structure in 
optical microscopy. All formulations showed zero order drug release by diffusion 
mechanism. The stability studies showed that proniosomal gels were stable at 4 to 
8°C and 25±2°C. The above results indicated that the proniosomal gels of could be 
formulated for controlled release of Lisinopril. 
 
M.A. Shatalebi39 et al., (2010), formulated the N-acetyl glucosamine (NAG)  
niosomes and investigated its flux across excised rat skin using Franz diffusion cells. 
The drug assay was performed by a novel and specific high performance liquid 
chromatography method. Niosomal vesicles were further characterized by optical and 
scanning electron microscopy and particle size analysis. Niosomes prepared with 
Span 40 produced a drug encapsulation of about 50%. The vesicle size was markedly 
dependent on the composition of the niosome formulations and was in range of 500-
4500 nm (Span 80 < Span 60 < Span 40 niosomes). Span 40- niosomes provided a 
higher NAG flux across the skin than Span 60- and Span 80-nisomes. All 
formulations significantly improved the extent of drug assessed to be localized in the 
skin (P< 0.05), as compared to NAG hydroalcoholic (HA) solution. Our study 
demonstrated the potential of niosomes for improved NAG localization in the skin, as 
needed in hyperpigmentation disorders. 
 
Ibrahim A. Alsarra40 (2008), prepared Piroxicam-loaded niosomes and characterized 
for surface morphology, entrapment efficiency and in vitro permeation across excised 
rat skin from various proniosome gel formulations using Franz diffusion cells. 
Proniosomes prepared with Span 60 provided a higher piroxicam flux across the skin 
than did those prepared with Tween 80. Niosomes prepared using Span 60 showed a 
higher release rate than those prepared using non-ionic surfactants, Span 20 and Span 
80, while those prepared from Tween showed higher release rate than formula 
prepared with Span. This indicates that lipophilicity and hydrophilicity of surfactant 
has a main role in release rates of piroxicam. Particle size of piroxicam niosomal 
vesicles formed by proniosome was determined by scanning electron microscopy. The 
encapsulation efficiency was evaluated by a specific high performance liquid 
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chromatography method. Niosomes formed from using Spans and Tweens exhibited 
very high encapsulation efficiency. The results are very encouraging and suggest that 
niosomes can act as promising carriers offering an alternative approach for 
transdermal delivery of piroxicam. 
 
N.Pavala rani41 et al., (2010), prepared niosomes of rifampicin and gatifloxacin by 
lipid hydration technique using rotary flash evaporator. The prepared rifampicin and 
gatifloxacin niosomes showed a vesicle size in the range of 100-300nm, the 
entrapment efficiency were 73% and 70% respectively. The invitro release study 
showed that 98.98% and 97.74% of release of rifampicin and gatifloxacin niosomes 
respectively. The bactericidal activities of the niosomal formulation were studied by 
BACTEC radiometric method using the resistant strains (RF 8554) and sensitive 
strains (H37Rv) of Mycobacterium tuberculosis which showed greater inhibition and 
reduced growth index. 
 
Arora Rajnish42 et al., (2010), formulated vesicles containing Ketoconazole using 
different non-ionic surfactants by Thin film hydration technique. The results 
confirmed that the relative slow release pattern of the entrapped drug from niosomes.   
 
Anita R. Desai43 et al., (2010), prepared niosomes containing α-lipoic acid. by 
reverse phase evaporation method using span and tween (20 and/or 60). The 
preparations were characterize with respect to size reduction, entrapment efficiency, 
in-vitro drug release profile and stability under specific conditions. The diameter of 
niosomes ranges from 1-3μm with spherical/ oval in shape. Higher cumulative release 
was observed with 76.202 % for span-20, 69.72% for span-60, 81.78 % for tween-20 
and 84.06 % for tween-60 respectively. Stability studies proved that optimum storage 
condition for niosomes was found to be 4°c. 
 
Pandey Shivanand44 et al., (2010), used Thin film Hydration Technique to prepare 
Cefpodoxime proxetil encapsulated niosomes with various surfactants like Span 20, 
40 and 80. The incompatibility between the drug and excipients shows that span is 
suitable for cefpodoxime proxetil to prepare niosomes. The in vitro release studies 
and kinetic study declared the release is zero order and in controlled manner, so there 
will be not chances of dose dumping during usage. 
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Ismail A. Attia 45 et al., (2007), improved poor and variable oral bioavailability of 
Acyclovir using niosmal formulation. The nonionic surfactant vesicles were prepared 
by the conventional thin film hydration method. The lipid mixture consisted of 
cholesterol, span 60, and dicetyl phosphate in the molar ratio of 65:60:5, respectively. 
The percentage entrapment was 11% of acyclovir used in the hydration process. In 
vitro drug release profile was found to follow Higuchi’s equation for free and 
niosomal drug. The niosomal formulation exhibited significantly retarded release 
compared with free drug. The in vivo study revealed that the niosomal dispersion 
significantly improved the oral bioavailability of acyclovir in rabbits after a single 
oral dose of 40 mg kg−1. The average relative bioavailability of the drug from the 
niosomal dispersion in relation to the free solution was 2.55 indicating more than 2-
fold increase in drug bioavailability..In conclusion, the niosomal formulation could be 
a promising delivery system for acyclovir with improved oral bioavailability and 
prolonged drug release profiles. 
  
Giulio Caracciolo46 et al., (2008), prepared niosomal vesicles (Niosomes) using 
binary mixture of polysorbate 20 (Tween 20) and Cholesterol in aqueous solution. 
And investigated by means of synchrotron small angle X-ray scattering (SAXS). 
Solid-supported niosomal membranes at full hydration exhibit the same structural 
properties, as determined by in situ energy dispersive X-ray diffraction (EDXD), than 
their counterpart in solution. Both Niosomes and solid-supported niosomal 
membranes are made of highly swollen bilayers rich in Tween 20 coexisting with 
Cholesterol crystallites. EDXD patterns from oriented samples suggest that at least 
some Cholesterol crystals are aligned along the normal to the solid support. 
 
Elsie Oommen47 et al., (1999), prepared Methotrexate- β-Cyclodextrin (MTX- βCD) 
complex entrapped niosomes by lipid layer hydration method. The niosomal 
entrapment efficiency was higher in the case of MTX - βCD complex (84%) than with 
the plain drug (67%). Comparison of the drug release profile revealed a relatively 
slow release pattern of the entrapped drug complex from the vesicles as compared to 
plain MTX encapsulated niosomes. Better stability on storage was also observed with 
the niosome entrapped complex. The complex entrapped niosomes produced an 
improved anticancer activity as evident by enhanced volume doubling time and 
growth delay. 
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Ling HU48 et al., (2008), established a preparation method for the phycoerythrin 
subunit (PE-sub) liposome. The optimum preparation conditions of the PE-sub 
liposome were found: a phosphatidylcholine-to-cholesterin ratio of 1:2, a PE-sub-to–
lipid ratio of 1:30, 20 ml buffer volume, 10 min sonication time, and an average 
encapsulation rate of up to 47.2%. The particle size ranged from 80 to 200 nm, and 
the average particle diameter was 136 nm. At a concentration of 100 μg/ml, the 
transfection rate of the PE-sub liposome reached 18% at 2 h and 24% at 4 h, and 
remained steady at 5–6 h. The half lethal dose of PDT on HepG2 was 75 μg/ml, 
whereas the cell survival rate of HL7702 reached 80% at the same dosage. 
 
Bin Shi49 et al., (2006), formulated a series of novel niosomes with the amphiphilic 
copolymer of poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl 
cyanoacrylate) (PEG-PHDCA) acted as surface modification materials and 
Hydroxycamptothecin (HCPT) was used as a model drug. This work concentrated on 
the effects of PEG chain length and particle sizes on the niosomes surface properties, 
in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor 
activity. Within the range of PEG Mw from 2000 to 10000, the increasing zeta 
potential (from -16.08 to -5.25 mv) and thicker fixed aqueous layer (3.82 to 5.78 nm) 
would facilitate the niosomes stealth effects, while the reduced PEG chain density 
(from 0.53 to 0.17 PEG/nm2) and the quickened speed of drug release would diminish 
the effects. As a result, the PEG5000-PHDCA niosomes had the least phagocytic 
uptake, the longest half-life of 11.46 h and the best tumor inhibition rate of 97.1%.  
 
Anil Vangala50 et al., (2006), improved the stability of 
Dimethyldioctadecylammonium (DDA) without undermining their potent 
adjuvanticity by incorporating into non-ionic surfactants, such as 1-monopalmitoyl 
glycerol (MP), in addition to cholesterol (Chol) and trehalose 6,60-dibehenate (TDB), 
using lipid hydration method. Differential scanning calorimetry revealed a reduction 
in the phase transition temperature (Tc) of DDA-based vesicles by 12°C when MP 
and cholesterol (1:1 molar ratio) were incorporated into the DDA system. 
Transmission electron microscopy (TEM) revealed the addition of MP to DDA 
vesicles resulted in the formation of multi-lamellar vesicles. Environmental scanning 
electron microscopy (ESEM) of MP–Chol–DDA–TDB (16:16:4:0.5-mol) indicated 
that incorporation of antigen led to increased stability of the vesicles, perhaps as a 
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result of the antigen embedding within the vesicle bilayers. At 4°C DDA liposomes 
showed significant vesicle aggregation after 28 days, although addition of MP–Chol 
or TDB was shown to inhibit this instability. Alternatively, at 25°C only the MP-
based systems retained their original size. The presence of MP within the vesicle 
formulation was also shown to promote a sustained release of antigen in-vitro. 
 
Gupta Naveen51 et al., (2010), formulated and evaluated Oflaxacin niosomes. In the 
present investigation nine formulations of Niosomal drug delivery system of ofloxacin 
with non ionic surfactant, span 60, in various proportions were prepared and evaluated 
for Morphological characterization, Encapsulation efficiency, In-vitro drug release 
study, Drug release kinetic data analysis, Stability study, Test for significance, Zeta 
potential analysis, Ocular irritation test, Estimation of minimum inhibitory 
concentration, In vivo study. Niosomes formed from span 60 and cholesterol in the 
ratio 200:100 (in mol) is a promising approach to improve the bioavailability of 
Ofloxacin even for an extended period of time which showed good physicochemical 
properties, good stability and controlled drug release pattern, thereby improving the 
bioavailability of the drug. 
 
S.Sambhakar52 et al., (2011), prepared niosomes containing Cefuroxime axetil was 
by film formation method by Span 40, 60 and 80. It is characterised by SEM for 
particle size and morphology. The vesicle size was found to be less than 5 μm and its 
polydispersity index was very low. Entrapment efficiency was found as Span 60 > 
Span 40 > Span 80. The in-vitro-release study indicated the controlled release profile 
of niosomes. Absorption study by everted-sac method showed that maximum 
absorption was found in case of niosomes containing bile salts and Span 60 followed 
by niosomes containing Span 60 only and then Span 40. Stability study indicated that 
on incorporation of bile salt upto 7.5 µM in the vesicle as integral component, the 
stability was maximum on exposure to 20 µM bile salt, whereas we omit 
incorporation of bile salt in vesicles, it showed least stability. 
 
K. Srikanth53 et al., (2010), prepared Meloxicam entrapped niosomes prepared by 
Thin film hydration technique using Nonionic surfactants (Span-80, Span-60, Tween-
80 and Tween-60), Cholesterol and drug in different ratios. The prepared niosomes 
appeared as round in shape and size range was found to be 1.54 – 2.64μm. Among all 
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formulations FS804 (surfactanant: drug: cholesterol, 2:1:1) shows high entrapment 
efficiency and consistent drug release pattern.The iv-vivo studies were demonstrated 
that niosomal gel was (FS804) shown better pharmacological activity than the 
conventional meloxicam gel. Based on the results it was concluded that niosomal 
preparation offers more advantages than the conventional preparation. 
 
Rishu Kakkar54 et al., (2011), prepared niosomes containing Valsartan and 
characterised for encapsulation efficiency, shape, size and in vitro drug release and 
stability study. The results showed that valsartan in all the formulations was 
successfully entrapped and a substantial change in release rate and an alteration in the 
encapsulation efficiency of valsartan from proniosomes were observed upon varying 
the type of surfactant and cholesterol content. The encapsulation efficiency of 
proniosomes prepared with Span 60 was superior to that prepared with Span 40. A 
preparation with 9:2:9 ratio of Span 60, cholesterol and lecithin gave maximum 
encapsulation efficiency (71.50%) and release results (Q24h= 75%) as compared to 
other compositions. Proniosomal formulations showed fairly high retention of 
valsartan inside the vesicles at refrigerated temperature (4-8°C) up to 1 month.  
 
Mohammed Shafik El-Ridy55 et al., (2011), Prepared Pyrazinamide (PZA) niosomes  
using different molar ratios of Span 60 and Span 85, with cholesterol (CH) i.e. Span: 
CH (1:1) and (4:2). Dicetyl phosphate and stearyl amine were used in preparation of 
negative and positively charged niosomes, respectively. Free PZA was separated by 
cooling centrifugation and estimated spectrophotometrically at 268.4 nm. Niosomes 
were characterized by electron microscopy and differential scanning calorimetry. The 
highest percentage PZA entrapped was obtained using Span 60 and the molar ratio 
(4:2:1) negatively charged niosomes. This was followed by the neutral PZA neutral 
(4:2) Span 60 niosomes. 
 
Mohamed S. El-Ridy56 et al., (2011), formulated silymarin niosomes with enhanced 
activity and limited side effects. Silymarin loaded niosomes were prepared using 
different non-ionic surfactants (NIS), cholesterol (Ch) and different charge inducing 
agents (CIA) in molar ratios (1:1:0.1) and (2:1:0.25). The effect of components molar 
ratio and effect of surface charges on the percentage drug encapsulated were 
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investigated. Characterization of prepared niosomes was performed via transmission 
electron microscopy (TEM), differential scanning calorimetry (DSC), particle size 
analysis and also investigation of the in vitro release profiles. Selected silymarin 
niosomal formulations were evaluated for their hepatoprotective activity against 
carbon tetrachloride (CCl4) induced oxidative stress in albino rats. Biochemical 
parameters like serum glutamate oxaloacetic transaminase (SGOT), serum glutamate 
pyruvate transaminase (SGPT) and serum alkaline phosphatase (SALP) were used to 
measure the degree of liver protection. Silymarin niosomal formulations produced a 
significant decrease in both transaminase levels as well as in SALP level in 
comparison with administered silymarin suspension.  
 
Raj K. Keservani57 et al., (2011), determined the effect of different process variables 
on the preparation of baclofen vesicles (Niosomes) and results that vesicle size 
increases on entrapment of drug. Effect of amount and type of surfactant shows 
niosome size directly       proportional to the HLB value of the surfactants. On 
increasing the cholesterol content of bilayer shows decrease rate of release of 
encapsulated material. Methods of preparation can also affect and produce different 
sized niosomes when prepared by different methods. Osmotic effect of niosomes in 
hypertonic media produces Shrinked type of niosomes whereas in hypotonic media 
niosomes are Swells or burst type. 6 ml hydration medium and 4 h hydration time for 
maximum % drug entrapment that is 87.90±0.18 % and 94.81±0.56 % respectively.  
 
C. P. Jain58 et al., (1995), prepared niosomes (non-ionic, surfactant-based vesicles) 
containing rifampicin of 8- 15 µm in diameter using Span-85 and cholesterol in 
various molar fractions. The process variables that could affect the physical 
characteristics of niosomes and in vitro release of the drug from the niosomes were 
studied and optimized. In vivo distribution studies of the prepared niosomes found 
that 65% of the drug could be localized in the lungs by controlling the niosome size. 
 
Waraporn Suwakul59 et al., (2006), formulated and evaluated Propylthiouracil 
(PTU) niosomes. The results revealed that niosomes readily formed from various 
compositions of nonionic surfactant and cholesterol, with or without a stabilizer. 
Entrapment of PTU in niosomes depended on bilayer composition. The release of 
PTU from all niosomal formulations studied was retarded and followed the first-order 
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kinetics. Degree of slow release had a negative correlation with drug entrapment. The 
release rate also depended on the physical state of the bilayer. The results of this study 
indicate that PTU niosomes were able to control the release of PTU and might be of 
value to develop further into topical formulations. 
 
Meiying Ning59 et al., (2005), prepared and optimized the Insulin loaded niosomes. 
The results showed optimized niosomes prepared in this study had niosomal 
entrapment efficiency 26.68±1.41% for Span 40 and 28.82±1.35% for Span 60, 
respectively. The particle sizes of Span 40 niosomes and Span 60 niosomes were 
242.5±20.5nm and 259.7±33.8 nm, respectively. Compared with subcutaneous 
administration of insulin solution, the relative pharmacological bioavailability and the 
relative bioavailability of insulin-Span 60 vesicles group were 8.43% and 9.61%, and 
insulin-Span 40 niosomes were 9.11% and 10.03% (p > 0.05). Span 60 and Span 40 
niosomes were both higher than blank Span 40, Span 60 vesicles, and free insulin 
physical mixture groups (p < 0.05). The results indicates insulin-Span 60, Span 40 
niosomes had an enhancing effect on vaginal delivery of insulin. 
 
Ajay B. Solanki60 et al., (2010), prepared Aceclofenac encapsulated niosomes by thin 
film hydration technique. A 32 factorial design was utilized to study the effect of the 
molar ratio of drug to lipid (X1) and volume of hydration medium (X2) on percentage 
drug entrapment (PDE) and vesicle size. Selected batches of niosomes were 
incorporated in to carbopol gel matrix to prepare the niosomal gel formulations, 
which were evaluated for in-vitro release, skin permeation and in vivo studies. It was 
evident from the derived polynomial equations and constructed contour plot, a 
decrease in the level of X1 and an increase in the X2 lead to an increase in PDE and 
decrease in vesicle size. The polynomial equations and contour plot predicted the 
levels of independent variables X1 and X2 (0.19 and 0.46 respectively), for 
maximized response of PDE with constraints on vesicle size. Each of the prepared 
niosomal gel formulations significantly improved (P<0.05) cumulative amount of 
drug permeated, steady state transdermal flux and increase in paw thickness. Among 
the niosomal gel formulations, NA6 (prepared at high level of X1 and medium level 
of X2) showed best permeation and effectiveness may be due to efficient hydration of 
the film and more total amount of drug entrapped. 
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Chawda Himmat Singh61 et al., (2011), designed suitable niosome-encapsulated 
drug delivery for nimesulide and evaluated the vesicle size, encapsulation efficiency, 
in vitro release and physical stability of the system. Non-ionic surfactants used were 
span 20, 40, 60 and cholesterol was used in different molar ratios. The niosomes 
prepared by lipid film hydration method were multilamellar vesicles (MLVS) and 
niosomes prepared by ether injection technique were unilamellar vesicles (ULVS) or 
oligolamellar vesicles. The higher entrapment efficiency was observed with MLVS 
prepared from span 60 and cholesterol in an 80:70 molar ratio. The release pattern 
shown by these formulations were zero order & Higuchi diffusion controlled 
mechanism. The physical stability study show that niosomal preparation stored at 
refrigerated temperature for 60 days show maximum drug retained for all the 
formulation compare to room temperature and elevated temperature conditions. 
 
Muhammad Naveed Yasin62 et al., (2012), prepared Chloramphenicol niosomes 
using two different ratios of cholesterol, drug and surfactant, termed as EIN-1 (drug: 
surfactant: surfactant, 1:1:1), EIN-2 (1:1:2) by ether injection method and their 
entrapment efficiency, particle size. The in vitro drug release pattern was observed for 
ten hours. The EIN-2 showed 90% entrapment and released 81% of entrapped drug 
after 10 hours. Zeta potential & viscosity were determined and in-vivo comparison 
was made with Chloramphenicol eye drops where it exhibited C max of 15μg/ml. 
Stability studies were done to determine shelf life. MIC of selected strain of S. aureus 
was also determined. EIN 2 niosomal suspension was In-vitro studies are encouraging 
as niosomes released about 75% of total entrapped drug by EIN-1 and 81% of total 
entrapped drug by EIN 2.compared with Chloramphenicol eye drops in experimental 
conjunctivitis in albino rabbits.  
 
P.U.Mohamed Firthouse63 et al., (2011), prepared Miconazole niosomes by varying 
the cholesterol and surfactant ratios as 1:0.5, 1:1, and 1:1.5. Each formulation was 
evaluated for percentage of drug entrapment and for their cumulative drug release. 
Formulation with 1:1 CHOL: SA ratio, the concentration of SA was increased and it 
has shown 92.10 % drug release in 24 hours. The release showing required amount of 
drug release per day as well as extended for the required day is the optimized 
formulation. Hence, B (1:1) formulation is the optimized one. 
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A. Abdul Hasan Sathali64 et al., (2010), formulated niosomes of Terbinafine 
hydrochloride by thin film hydration method using different ratios of non ionic 
surfactant (tween 20, 40, 60, and 80) and cholesterol with constant drug 
concentration. The prepared formulations were evaluated for its vesicle size (by 
AFM), entrapment efficiency (by dialysis method) in vitro release studies and 
antifungal activities. Increase in surfactant concentration, increased the entrapment 
efficiency (up to 84.92%) and the formulation with surfactant cholesterol ratio 2:1 in 
each group of surfactant showed good entrapment. Niosomal preparation were tested 
for in vitro antifungal activity using the strain Aspergillus niger and compared with 
pure drug solution (as standard). The best formulation with maximum zone of 
inhibition and sustained release of drug (tween 40 nisomes) incorporated into gel 
bases and evaluated. The studies revealed that gel containing total niosomes possess 
maximum zone of inhibition values (12mm) initially followed by sustained release 
(12mm-16mm) comparing to gel containing drug entrapped niosomes, gel containing 
pure drug and marketed preparation. 
 
Anupriya kapoor65 et al., (2011), formulated Acyclovir loaded niosomes formed 
using sorbitan esters (Span 20, 40, 60, and 80) and cholesterol in different molar ratio. 
Niosomes were formed using Reverse phase evaporation method. The so formed 
niosomes were characterized for their in vitro drug release efficiency. The results 
indicated that more sustained release pattern can be obtained by incorporating the 
drug in niosomes formed with Span60.                                                                                                    
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5. MATERIALS AND METHODS 
5.1. MATERIALS 
Table:2 Materials used                          
 
S.NO 
 
Materials 
 
source 
 
1. 
 
Zidovudine 
 
Bafna pharmaceuticals,Mumbai 
 
2. 
 
Potassium di hydrogen phosphate 
 
S.D. Fine Chem Ltd, Boisar 
 
3. 
 
Disodium hydrogen phosphate 
 
S.D. Fine Chem Ltd, Boisar 
 
4. 
 
Sodium chloride 
 
S.D. Fine Chem Ltd, Boisar 
 
5. 
 
Sorbitan mono laurate (span 20) 
 
S.D. Fine Chem Ltd, Boisar 
 
6. 
 
Polysorbate 20 (tween 20) 
 
S.D. Fine Chem Ltd, Boisar 
 
7. 
 
Cholesterol 
 
Qualigens Chem Ltd, Boisar 
 
8. 
 
Chloroform 
 
S.D. Fine Chem Ltd, Boisar 
 
9. 
 
Methanol 
 
S.D. Fine Chem Ltd, Boisar 
 
10. 
 
Dicetyl phosphate 
 
S.D. Fine Chem Ltd, Boisar 
 
11. 
 
Triton X – 100 
 
S.D. Fine Chem Ltd, Boisar 
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5.2. INSTRUMENTS 
Table:3 Instruments used 
 
 
 
 
 
S.NO 
 
Equipments 
 
Company 
 
1. 
 
Rotary flash evaporator 
 
Equitron, Mumbai. 
 
2. 
 
Probe sonicator 
 
Bandelin, Germany 
 
3. 
 
UV- Visible spectrophotometer 
 
Shimadzu corporation, Japan 
 
4. 
 
Stability chamber (120 litres) 
 
Osworld, Mumbai 
 
5. 
 
Single pan electronic balance 
 
Shimadzu corporation 
 
6. 
 
Magnetic stirrer 
 
Remi motor Ltd, Mumbai 
 
7. 
 
pH meter 
 
ELICO, Pvt, Ltd.Chennai. 
 
8. 
 
Autoclave 
 
Dalal, Chennai. 
 
9. 
 
Laminar air flow bed 
 
Klenzoids, Mumbai 
 
10. 
 
Hot air oven 
 
Biochem, Mumbai. 
 
11. 
 
IR Spectrophotometer 
 
Perkin Elmer, Germany 
 
12. 
 
Cooling centrifuge 
 
Remi motor Ltd. Mumbai. 
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Solubility 
Sparingly soluble in water.  Soluble in ethanol. 
 
Dose 68  
Dose by mouth 500 – 600 mg in 2 – 3 divided doses. 
Child over three months 360 – 480 mg/m2 daily in 3 – 4 divided doses. 
By intravenous over1 hr, 1-2 mg/kg. 
 
Mechanism of action 
Zidovudine is a nucleoside reverse transcriptase inhibitor which is 
phosporylated by host cell enzymes to give 5´triphosphate derivative. The moiety 
competes with equivalent host cellular triphosphate substrate for proviral DNA 
synthesis by viral reverse transcriptase (viral RNA dependent DNA polymerase), 
eventually incorporation of the 5´triphosphate moiety into the growing viral DNA 
chain results in chain termination. 
 
Pharmacokinetics 
It is generally administered orally a twice daily. But can also given by 
intravenous infusion. The bioavailablity is 60-80%, and the peak plasma 
concentration at 30 min. Half life of zidovudine is 1 hour and the intracellular half life 
of the active triphosphate is 3 hours. The concentration of cerebrospinal fluid is 65% 
of the plasma level. Most of the drug is metabolised to the inactive glucuronides in the 
liver, and 20% 0f active form being excreted in urine. 
 
Side effects 
Blood disorders – anaemia, neutropenia, and thrombocytopenia. 
GI disturbances – nausea, vomiting,  abdominal pain and diarrhoea. 
CNS effects – headache, insomnia, and dizziness. 
 
Therapeutic indications 
It can prolong life in HIV infected individual and diminish HIV associated 
Dementia. 
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5.4. EXCIPIENTS LITERATURE 69  
Cholesterol 
Synonym 
 Cholesterin 
 
Chemical formula 
 Cholest – 5 – en – 3β  - ol 
 
Empirical formula 
 C27 H46O 
 
Molecular weight 
 386.67 
 
Structural formula 
OH
H
CH3
H
H
H
CH3
H
H
CH3
CH3
CH3
 
 
Functional category 
 Emulsifying agent, Emollient 
 
Application in pharmaceutical formulations 
• It is used as emulsifying agent in cosmetic and topical pharmaceutical 
formulation. 
 
Description 
• White or faintly yellow colour. 
• Almost odourless. 
• Pearly leaflets, needles, powder or granules. 
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Typical properties 
Density    : 1.052 g/cm3 
Boiling point    : 360oC 
Melting point    : 147 – 150oC 
Specific rotation : -34o to -38o 
 
Solubility 
• Soluble in acetone, vegetable oil. 
• Soluble in organic solvents like benzene, methanol, hexane, chloroform, 
ethanol, ether. 
 
Stability and storage conditions 
 Cholesterol is stable and should be stored in a well closed container, protected 
from light. 
 
Incompatibilities 
Precipitated by digitonin. 
 
Sorbitan mono laurate 
Synonym:      
Span 20 
 
Chemical name:  
Sorbitan monododecanoate. 
 
Empirical Formula:  
C15H34O6 
 
Molecular weight:  
346 
 
Structural Formula 
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Functional Category: 
Nonionic surfactant, emulsifying agent, solubilising agent, wetting agent. 
 
Application in Pharmaceutical Formulation: 
• They are widely used in pharmaceutical formulation as emulsifying agent in the 
preparation of creams, emulsions and ointments for topical application. 
• They are widely used in cosmetics, food products, pharmaceutical formulations 
as lipophilic nonionic surfactant. 
 
Description: 
• Yellow viscous liquid 
• Distinctive odour and taste. 
 
Typical properties: 
 Density                - 1.01 gm/cm3 
 Surface tension    - 28(mN/M) 
            HLB value           - 8.6 
 
Solubility: 
• Soluble or dispersible in oils.  
• They are also soluble in most of organic solvents. 
 
Stability and Storage: 
 Stored in a well closed container in a cool dry place. 
 
Polysorbate 20 
Synonym 
Tween 20 
 
Chemical name 
Polyoxyethylene 20 sorbitan monolaurate. 
 
Empirical formula 
C58 H114O26 
 
Molecular weight  
1128 
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Structural formula 
 
H (OC2H4) OCH
H C
H CO (C2H4O)
CH2O (C2H4O) OCR
HCO (C2H4O)
CH2
O
 
 
Functional category 
 Non ionic surfactant, emulsifying agent, solubilizing agent, wetting agent. 
 
Application in pharmaceutical formulation 
• Used as emulsifying agent in the preparation of oil in water emulsion. 
• As a solubilizing agent for various essential oils and oil soluble vitamins. 
• It is widely used in cosmetics and food products. 
 
Description 
• Have a characteristic odour and warm, slight bitter taste. 
• They are yellow oily liquid at 25oC.  
 
Typical properties 
Specific gravity   : 1.1 
HLB value  : 16.7 
Viscosity  :  400 (millipascals) 
 
Solubility 
• It is soluble in ethanol and water. 
• Insoluble in mineral oil, vegetable oil. 
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Stability and storage conditions 
 Stored in a well closed container. 
            Protected from light, in a cool, dry place. 
 
Incompatabilities 
 Discoloration and or precipitation occur with various substances like phenols, 
tannins, tar like substances. 
 
Triton X – 10070  
Chemical name 
 Polyoxyethylene octylphenyl ether 
 
Empirical formula 
 C34H62O11 
 
Molecular weight 
646 
 
Structural formula 
 
CH3C (CH3)2 CH2 - C O (CH2CH2O)x H
CH3
CH3  
 
Functional category 
 Nonionic surfactant, emulsifying agent, dispersing agent. 
 
Application in pharmaceutical formulation 
• They are commonly used in some formulation for emulsion polymerizations. 
• It is used as wetting agent for affecting certain staining protocols in microscopy 
and histology laboratory. 
 
Description 
• Viscous liquid 
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5.5. METHODS 
5.5.1. Reagent used 
Preparation of release media71 
2.38 gm of disodium hydrogen phosphate, 0.19 gm of potassium dihydrogen 
phosphate and 8gm of sodium chloride were dissolved in sufficient amount of 
distilled water to produce 1000ml and pH adjusted to 7.4, if necessary. 
 
5.5.2. Determination of Absorbance maximum (λmax)72 
  Zidovidine was dissoled in phosphate buffer saline pH 7.4. Solution with 20 
µg/ml concentration was prepared by suitable dilution.     
 
The Zidovudine drug in solution was scanned in UV spectrophotometer from 
200 to 400 nm using phosphate buffer saline pH 7.4 as blank. Absorbance maximum 
was determined as 267 nm. The drug was later quantified by measuring the 
absorbance at 267 nm in phosphate buffer saline pH7.4.                 
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5.5.3. Standard curve for Zidovudine (by UV metohod)73 
Preparation of primary stock solution 
 Zidovudine 100 mg was weighed and dissolved in phosphate buffer saline pH 
7.4 in a 100 ml volumetric flask. The flask was shaken and volume was made up to 
the mark with phosphate buffer saline pH 7.4 to give a solution containing 1000 
μg/ml.  
 
Preparation of secondary stock solution 
 From the primary stock solution, pipette out 2 ml and placed into 100 ml 
volumetric flask. The volume was made up to mark with phosphate buffer saline pH 
7.4 to give a stock solution containing 20 μg / ml. 
 
Preparation of sample solution 
Appropriate volumes of aliquots (1 to 10 ml) from standard Zidovudine 
secondary stock solution were transferred to different volumetric flasks of 10 ml 
capacity. The volume was adjusted to the mark with phosphate buffer saline pH 7.4 to 
obtain concentrations of 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 μg / ml. Absorbance of 
each solution against phosphate buffer saline pH 7.4 as blank were measured at 267 
nm and the graph of absorbance against concentration were plotted and shown in 
Figure.8. 
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Standard curve data for Zidovudine (By U.V method) 
Table:4 
 
Concentration 
in µg/ml 
 
Absorbance at 
267 nm 
 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
 
0.124 
0.195 
0.290 
0.385 
0.483 
0.576 
0.671 
0.769 
0.864 
0.939 
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6. RESEARCH ENVISAGED 
6.1. INFRARED SPECTROSCOPIC STUDIES 74 
IR study was carried out for identification of pure drug. IR spectroscopy 
(using Perkin Elmer) by KBr pellet method was carried out on drug. They are 
compressed under 15 tones pressure in a hydraulic press to form a transparent pellet. 
The pellet was scanned from 4000 to 400 cm-1 in a spectrophotometer and peaks 
obtained were identified. 
 
6.2. OPTIMIZATION PROCESS FOR NIOSOME PREPARATION 
Empty vesicles were prepared by Thin film hydration technique. A liquid 
phase was prepared by dissolving accurately weighed quantities of surfactant and 
cholesterol was dissolved in chloroform methanol mixture ratio (2:1v/v) in 100 ml 
round bottom flask. The solvent mixture was removed from the liquid phase using 
rotary evaporator at 45-60°C and the speed of rotation was varied like 75rpm, 
100rpm, 125rpm and 150rpm to obtain a thin film on the wall of the flask. 
Simultaneously the residual solvent was completely removed by keeping the flask 
under the vaccum. The thin film was hydrated with phosphate buffer saline pH 7.4 by 
varying hydration volume 5ml, 10ml and hydration time of 30, 60 and 120 min at a 
temperature of 60±2°C. The vesicle size and appearance of empty vesicle were noted. 
 
6.3. FORMULATION OF ZIDOVUDINE NIOSOMES 19 
Zidovudine loaded niosomes were prepared by Thin film hydration technique. 
Accurately weighed quantity of cholesterol and surfactant were dissolved in 
chloroform methanol mixture ratio (2:1v/v) in a 100 ml volumetric flask. The 
weighed quantity of drug and dicetyl phosphate was added to the solvent mixture. The 
solvent mixture was removed from liquid phase using rotary evaporator at 60°C to 
obtain a thin film on the wall of the flask at a rotation speed of 150 rpm. The complete 
removal of solvent can be ensured by applying vaccum. The dry lipid film was 
hydrated with 5 ml phosphate buffer saline of pH 7.4 at a temperature of 60±2°C for a 
period of 2 hour until the formation of niosomes. All the batches were subjected to 
sonication process for 2 min using probe sonicator. The ratios of cholesterol and 
surfactant used in the formulation were tabulated (table 5). 
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COMPOSITION OF ZIDOVUDINE NIOSOMES 
Table:5 
 
Formulation 
code 
Zidovudine 
(mg) 
Surfactant 
Surfactant: 
Cholesterol 
(µM) 
F1 10 Span 20 100:100 
F2 10 Span 20 200:100 
F3 10 Span 20 300:100 
F4 10 Span 20 100:200 
F5 10 Span 20 200:200 
F6 10 Span 20 300:200 
F7 10 Span 20 400:200 
F8 10 Tween 20 100:100 
F9 10 Tween 20 200:100 
F10 10 Tween 20 300:100 
F11 10 Tween 20 100:200 
F12 10 Tween 20 200:200 
F13 10 Tween 20 300:200 
F14 10 Tween 20 400:200 
 
           Solvent: chloroform methanol mixture (2:1v/v) 
           Hydration time: 2 hour 
           Hydration media: Phosphate buffer saline pH 7.4 (5 ml) 
           Dicetyl phosphate: 15µM 
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6.4. EVALUATION OF ZIDOVUDINE NIOSOMES 
6.4.1. Removal of unentrapped drug from niosomes 21 
The unentrapped drug from niosomal formulation was separated by 
centrifugation method. The niosomal suspension was taken in centrifuge tube. The 
formulation was centrifuged at 15,000 rpm for 30 min using cooling centrifuge and 
temperature was maintained at 5°c. The supernatant was separated. Supernatant 
contained unentrapped drug and pellet contained drug encapsulated vesicles.  The 
pellet was resuspended in phosphate buffer saline pH 7.4 to obtain a niosomal 
suspension free from unentrapped drug.  
  
6.4.2. Encapsulation efficiency 
Drug entrapped vesicles were separated from unentrapped drug by 
centrifugation method. 0.5 ml of zidovudine loaded niosome preparation was added 
with 0.5 ml of 10% triton X 100 and mixed well then incubated for 1 hour. The triton 
X 100 was added to lyse the vesicles in order to release the encapsulated zidovudine. 
The solution was diluted with phosphate buffer saline pH 7.4 and filtered through 
whatmann filter paper. The filtrate was measured spectrophotometrically at 267 nm 
using phosphate buffer saline pH 7.4 and triton X 100 mixture as blank. 
 
      Amount of drug entrapped                       
Percent entrapment  =                                                         × 100 
     Total amount of drug added 
    
 
6.4.3. In vitro release study for niosomal preparation 26 
The niosomal formulation was taken in a dialysis membrane of 5 cm length 
and suitably suspended in a beaker containing 100 ml diffusion medium of phosphate 
buffer saline pH 7.4. The temperature of medium was maintained at 37±0.5°C. The 
medium was stirred by means of magnetic stirrer at a constant speed. 1 ml of sample 
was withdrawn at every 1 hour and replaced with 1 ml of fresh buffer, so that the 
volume of diffusion medium was maintained constant at 100 ml. The withdrawn 
samples were made upto 10 ml using phosphate buffer saline pH 7.4. The samples 
were measured spectrophotometrically at 267 nm.  
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6.4.4. Zeta potential 22 
The zeta potential of optimized zidovudine niosomal formulation was 
measured using Malvern zeta potential analyser. 
 
6.4.5. Scanning electron microscopy 27 
The optimized formulation was morphologically characterized by scanning 
electron microscopy (SEM). The sample for SEM analysis was mounted in the 
specimen stub using an adhesive small sample was mounted directly in scotsch double 
adhesive tape. The sample was analysed in hitachi scanning electrom microscope 
operated at 15 kv and photograph was taken. 
 
6.4.6. Sterility testing 70 
Sterility of prepared and optimized zidovudine niosomal formulation was 
evaluated by sterility test as per IP. The method selected for testing is Method І – 
Membrane Filtration Method. 
 
Preparation of Soya bean Casein Digest medium (SCDM) 
25 gm of dehydrated media was dissolved in 1000 ml of distilled water. The 
solution was boiled for 10 min. This solution was used as medium. The medium was 
cooled to room temperature and pH adjusted to 7.3±0.2. The medium was dispensed 
in suitable container and sterilized at 121°C for 15 min. 
 
Preparation of Fluid Thioglycollate medium (FTM)  
Dehydrated media 26 gm was dissolved in distilled water to get 1000 ml of the 
medium. It was boiled for 10 min. The medium was cooled to room temperature and 
pH adjusted to 7.2±0.2. The medium was sterilized at a temperature of 121°C for 15 
min. The sterilised media should not have more than upper one- third of the medium 
in pink colour. 
 
Preparation of Rinsing Fluid (Fluid A) 
1 gm of peptic digest of animal tissue was weighed and mixed up with small 
amount of hot water and made upto 1000 ml. The solution was filtered and pH 
adjusted to 7.1±0.2. The solution was then dispensed in suitable container and 
autoclaved for sterilization. 
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Procedure 
The vials containing zidovudine niosomes were broken open under aseptic 
condition provided by laminar air flow work station.  All precaution and preventive 
measures were taken to avoid contamination by the process or by the analyst. The 
drug solution was then passed through sterile membrane lodged on a membrane 
holder assembly. After passing through the solution, the membrane was rinsed three 
times with 100 ml of sterile peptone   (Fluid A). The membrane was cut into two 
halves using sterile scissors. One half of the filter paper was introduced into the 
container with SCDM and the other half into the container with FTM. 
 
SCDM containers were then incubated at 22.5±2.5°C and containers at 
32.5±2.5°C. The containers were observed for turbidity or appearance of growth of 
microorganisms for 14 days. Positive control and negative control tests were done to 
validate the sterility testing procedure. 
 
Negative control 
Negative control confirms the sterility of the sterilized media. It was then 
inoculated and observed for 14 days. Negative control was maintained for both the 
media and incubated in their appropriate temperature. 
 
Positive control  
Positive control confirms the suitability of the media for the growth of 
microorganism. The positive control for SCDM and FTM were inoculated with 
Bacillus subtilis suspension and incubated at 22.5±2.5°C and 32.5±2.5°C respectively 
for 14 days. The growth of microorganisms witnessed by the turbidity of the medium 
confirms the presence of nourishments favouring the microorganisms. 
 
6.4.7. Stability study of zidovudine niosomes 24       
The optimized zidovudine niosome formulation was examined for stability 
study. The formulations were taken in a 20 ml sealed glass vial and stored in three 
different environments such as 4°C, room temperature and 45°c/75% RH for a period 
of three months. Samples from each batch were withdrawn at the interval of one 
month and evaluated for entrapment efficiency and in vitro drug release.         
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7. RESULTS AND DISCUSSION 
7.1. Development of zidovudine niosomes 
 In this study, zidovudine loaded niosomes were prepared by Thin film 
hydration technique using cholesterol and non ionic surfactants such as span 20 and 
tween 20. Chloroform methanol mixture (2:1v/v) was used as solvent. 
 
  After evaporation of solvent from the formulation, thin film was formed. The 
thin film was hydrated and removed by phosphate buffer saline pH 7.4. Size of the 
vesicles in formulation was reduced by sonicating the formulation in Probe sonicator. 
 
 Formulations with different ratios of surfactant and cholesterol were prepared. 
Several physicochemical characteristics of niosomes such as morphology, vesicle size 
determination, drug release profile were investigated. And stability of optimized 
formulation at various temperatures was evaluated.  
 
Dicetyl phosphate (DCP) also included in the formulation as charge inducing 
agent. The inclusion of charge inducing agent (DCP) prevented the aggregation and 
fusion of vesicles. Integrity and uniformity also maintained by dicetyl phosphate. 
 
An effective niosomal drug delivery system should posses good physical and 
chemical stability on storage and should incorporate high drug loading with stable 
encapsulation. 
  
7.2. IR studies 
Pressed Pellet Technique was used to handle the sample in FTIR spectrometer. 
In this technique a required amount of sample was added and mixed well with 
potassium bromide and the mixture was pressed with special discs under high 
pressure into a transparent pellet and then inserted into special holder of IR 
spectrometer.  
 
The pellets were scanned from 4000 to 400 cm-1 in FTIR spectrophotometer 
and peaks obtained in both spectrums were identified. The wave number at which 
peaks appeared and peaks indicating functional groups are presented in table:6.   
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Table:6 
Frequency 
 
Group assigned  
Pure drug 
 
Physical mixture 
 
3402 
 
3401 
 
OH & NH - stretching 
 
2852 
 
2924 
 
CH – stretching 
 
1660 
 
1654 
 
C=O – stretching 
 
1094 
 
1106 
 
CO – stretching 
 
IR spectrums for pure drug alone and physical mixture of drug, surfactant, and 
cholesterol were taken. The spectrum of physical mixture was compared with 
spectrum of pure drug. Bands seen in pure drug also recognized in physical mixture. 
Hence there was no significant interaction between drug and excepients. 
    
7.3. Optimization of process related variables 
 The prepared niosomal vesicles were influenced by some factors like speed of 
rotation, hydration volume, hydration medium and vaccum. Before loading the drug, 
these factors should be optimized using empty vesicle. 
 
 The vaccum used for drying of thin film was 350 mmHg. Vaccum below 350 
mmHg was insufficient for complete removal of solvent from the formulation and 
resulted in aggregation of niosomes on hydration. The vaccum above 350 mmHg 
resulted rapid evaporation of solvent which leads to entrapment of air bubbles on the 
surface of film.  This caused poor entrapment of drug in niosomes and the vaccum of 
350 mmHg produced lipid film had appreciable drug entrapment in the niosomes. 
Hence 350 mmHg of vaccum was considered as optimum range. 
 
 The time of hydration of lipid film was carried from 60 -120 min. When 
hydration allowed to 120 min,  formed niosomes were spherical in shape and existed 
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in desired size range. So hydration time 120 min and hydration volume 5 ml were 
selected as optimum.  
 
Thickness and uniformity of thin film was influenced by speed rotation of 
round bottom flask. The optimum speed was selected to 150 rpm. At this speed of 
rotation, thin film formed was uniform. The bath temperature of rotary evaporator was 
maintained at 60±2°C as optimum. 
 
 
Optimization of process related variables 
Table:7 
Surfactant: 
Cholesterol 
Speed of 
Rotation 
(rpm) 
Hydration 
Time 
(min) 
Chloroform: 
methanol 
Hydration 
volume 
Vesicle 
Size 
(µM) 
 
100:100 
75 
100 
125 
150 
30 
60 
120 
120 
 
2:1 
 
 
5 ml 
 
10.29±1.48 
9.41±1.09 
9.11±1.88 
8.69±1.88 
 
 
Table:8 
Volume of 
hydration medium 
(ml) 
Hydration time 
(min) 
Percentage 
entrapment 
(%) 
3 60 60.74 ± 0.98 
4 60 68.84 ± 0.76 
4 60 73.38 ± 0.58 
5 120 89.45 ± 0.88 
5 180 81.45 ± 0.93 
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7.4. Evaluation of Zidovudine Niosomes 
7.4.1. Removal of unentrapped drug from Niosomes 
 The unentrapped drug from  niosomes was removed by centrifugation 
technique. The results are presented in following table, 
 
7.4.2. Percentage drug entrapment efficiency 
Table:9 
 
Formulation 
code 
Surfactant: 
Cholesterol 
(µM) 
 
Surfactant 
used 
Percentage of 
free Drug 
(%) 
Percentage 
entrapment 
Efficiency 
(%) 
F1 100:100 Span 20 37 63 
F2 200:100 Span 20 26 74 
F3 300:100 Span 20 32 68 
F4 100:200 Span 20 38 62 
F5 200:200 Span 20 28 72 
F6 300:200 Span 20 16 84 
F7 400:200 Span 20 29 71 
F8 100:100 Tween 20 32 68 
F9 200:100 Tween 20 19 81 
F10 300:100 Tween 20 27 73 
F11 100:200 Tween 20 29 71 
F12 200:200 Tween 20 15 85 
F13 300:200 Tween 20 8 92 
F14 400:200 Tween 20 24 76 
 
 
The entrapment efficiency of the niosomes is governed by the ability of 
formulation to retain drug molecule in aqueous core or in bilayer membrane of 
vesicles. After removal of unentrapped drug, the entrapment of all formulation was 
studied. Entrapment efficiency was varied with varying the surfactant and cholesterol 
ratio. Various factors like lipid concentration, drug to lipid ratio, and cholesterol 
content will change the entrapment efficiency. 
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 Entrapment efficiency of formulation F1 was found to be 63%. In formulation 
F2, increasing the surfactant concentration, entrapment efficiency was increased to 
74%. Further increasing the surfactant concentration in F3, the entrapment efficiency 
was decreased to 68%, due to very low concentration of cholesterol.    
 
So, to improve the entrapment efficiency cholesterol concentration was 
increased to 200µM in formulations F4, F5, F6, and F7. Because, increase the amount 
of cholesterol will improve the entrapment efficiency. But entrapment efficiency 
achieved in formulations F4, F5, F6, and F7 were 62%, 72%, 84%, and 71%. The drug 
entrapment was not improved satisfactorily. This is due to, surfactant used in those 
formulations was span 20. The span 20 is more hydrophobic,  hence the hydrophilic 
drug gets encapsulated in the aqueous core only.       
 
The formulations were tried with tween 20 in formulations F8, F9, and F10 
contained 100 µM of cholesterol and 100, 200, 300 µM of tween 20 respectively. The 
releases were accordingly, 68%, 81%, and 73%, due to low level of cholesterol 
concentration. 
 
So quantity of cholesterol was increased 200 µM in formulations F11, F12, F13 
and F14, entrapment efficiency was improved to 71%, 85%, 92% and 76% 
respectively. The increase in the entrapment efficiency is attributed to the ability of 
surfactant and cholesterol to cement the leaking space in the bilayer membrane, which 
in turn allows enhanced drug level in niosomes. Compared to span 20, the better 
entrapment efficiency was achieved in tween 20. This can be explained as the tweens 
are more water soluble, the hydrophilic Zidovudine drug, gets encapsulated as well as 
partitions into vesicle membrane. Hence formulation F13 was optimized one. 
 
7.4.3. In vitro release study 
 The release of Zidovudine from niosomes was determined using the 
membrane diffusion technique. Release study was carried for 24 hours and results are 
noted in following tables. 
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Table:10 In vitro drug release for F1 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.3 0.3 3.0 
2 0.8 0.803 8.03 
3 1.5 1.508 15.08 
4 1.6 1.615 16.15 
5 2.2 2.216 22.16 
6 2.4 2.422 24.22 
7 2.8 2.824 28.24 
8 3.3 3.328 33.28 
9 3.5 3.533 35.33 
10 4.1 4.135 41.35 
11 4.3 4.341 43.41 
12 4.7 4.743 47.43 
13 4.9 4.947 49.47 
14 5.3 5.348 53.48 
15 5.8 5.853 58.53 
16 6.1 6.158 61.58 
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Table:11 In vitro drug release for F2 
 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.8 0.8 8.0 
2 1.0 1.008 10.08 
3 1.1 1.11 11.10 
4 1.5 1.511 15.11 
5 2.2 2.215 22.15 
6 2.6 2.622 26.22 
7 3.0 3.026 30.26 
8 3.2 3.230 32.30 
9 3.3 3.322 33.22 
10 3.7 3.733 37.33 
11 4.2 4.237 42.37 
12 4.8 4.842 48.42 
13 5.4 5.448 54.48 
14 5.6 5.651 56.51 
15 6.8 6.856 68.56 
16 6.9 6.968 69.68 
17 7.2 7.269 72.69 
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Table:12 In vitro drug release for F3 
 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.3 0.3 3.0 
2 0.6 0.603 6.03 
3 1.4 1.406 14.06 
4 1.6 1.614 16.14 
5 2.3 2.316 23.16 
6 2.7 2.723 27.23 
7 2.9 2.927 29.27 
8 3.4 3.429 34.29 
9 4.8 4.834 48.34 
10 4.9 4.948 49.48 
11 5.1 5.149 51.49 
12 5.4 5.451 54.51 
13 5.5 5.554 55.54 
14 5.7 5.755 57.55 
15 6.4 6.457 64.57 
16 6.7 6.764 67.64 
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Table:13 In vitro drug release for F4 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.2 0.2 2.0 
2 0.4 0.402 4.02 
3 0.9 0.904 9.04 
4 1.0 1.009 10.09 
5 1.3 1.310 13.10 
6 1.4 1.413 14.13 
7 1.8 1.814 18.14 
8 2.2 2.218 22.18 
9 2.5 2.522 25.22 
10 2.6 2.625 26.25 
11 3.0 3.026 30.26 
12 3.1 3.130 31.30 
13 3.2 3.231 32.31 
14 3.5 3.532 35.32 
15 3.6 3.635 36.35 
16 3.8 3.836 38.36 
17 3.9 3.938 39.38 
18 4.0 4.039 40.39 
19 4.3 4.340 43.40 
20 4.7 4.743 47.43 
21 4.9 4.947 49.47 
22 5.0 5.049 50.49 
23 5.7 5.750 57.50 
24 5.9 5.957 59.57 
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Table:14 In vitro drug release for F5 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.2 0.2 2.0 
2 0.5 0.502 5.02 
3 0.7 0.705 7.05 
4 0.8 0.807 8.07 
5 1.3 1.308 13.08 
6 1.5 1.513 15.13 
7 1.9 1.915 19.15 
8 2.5 2.519 25.19 
9 2.6 2.625 26.25 
10 3.0 3.026 30.26 
11 3.1 3.130 31.30 
12 3.3 3.331 33.31 
13 3.6 3.633 36.33 
14 3.8 3.836 38.36 
15 4.2 4.238 42.38 
16 4.3 4.342 43.42 
17 4.5 4.543 45.43 
18 4.8 4.845 48.45 
19 5.1 5.148 51.48 
20 5.5 5.551 55.51 
21 6.0 6.055 60.55 
22 6.3 6.360 63.60 
23 6.5 6.563 65.63 
24 7.1 7.165 71.65 
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Table:15 In vitro drug release for F6 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.5 0.5 5.0 
2 0.7 0.705 7.05 
3 1.0 1.007 10.07 
4 1.5 1.510 15.10 
5 1.6 1.615 16.15 
6 1.8 1.816 18.16 
7 2.5 2.518 25.18 
8 2.8 2.825 28.25 
9 3.3 3.328 33.28 
10 3.4 3.433 34.33 
11 3.9 3.934 39.34 
12 4.1 4.139 41.39 
13 4.5 4.541 45.41 
14 4.7 4.745 47.45 
15 5.5 5.547 55.47 
16 5.7 5.755 57.55 
17 6.1 6.157 61.57 
18 6.6 6.661 66.61 
19 6.9 6.966 69.66 
20 7.2 7.269 72.69 
21 7.4 7.472 74.72 
22 7.6 7.674 76.74 
23 7.9 7.976 79.76 
24 8.1 8.197 81.97 
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Table:16 In vitro drug release for F7 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.6 0.6 6.0 
2 0.8 0.806 8.06 
3 1.5 1.508 15.08 
4 1.7 1.715 17.15 
5 2.0 2.017 20.17 
6 2.1 2.120 21.20 
7 2.6 2.621 26.21 
8 3.3 3.326 33.26 
9 3.4 3.433 34.33 
10 4.0 4.034 40.34 
11 4.9 4.940 49.40 
12 5.5 5.549 55.49 
13 6.3 6.355 63.55 
14 7.0 7.063 70.63 
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Table:17 In vitro drug release for F8 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.4 0.4 4.0 
2 0.8 0.804 8.04 
3 1.1 1.108 11.08 
4 1.9 1.911 19.11 
5 2.2 2.219 22.19 
6 3.4 3.422 34.22 
7 3.6 3.634 36.34 
8 3.9 3.936 39.36 
9 4.1 4.139 41.39 
10 4.5 4.541 45.41 
11 4.7 4.745 47.45 
12 5.0 5.047 50.47 
13 5.3 5.35 53.5 
14 5.9 5.953 59.53 
15 6.1 6.159 61.59 
16 6.5 6.561 65.61 
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Table:18 In vitro drug release for F9 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.9 0.9 9.0 
2 1.4 1.409 14.09 
3 1.5 1.514 15.14 
4 1.9 1.915 19.15 
5 2.4 2.419 24.19 
6 2.9 2.924 29.24 
7 3.2 3.229 32.29 
8 3.5 3.532 35.32 
9 3.6 3.635 36.35 
10 4.1 4.136 41.36 
11 4.8 4.841 48.41 
12 5.1 5.148 51.48 
13 5.3 5.351 53.51 
14 5.8 5.853 58.53 
15 6.1 6.158 61.58 
16 6.8 6.861 68.61 
17 7.4 7.468 74.68 
18 7.9 7.974 79.74 
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Table:19 In vitro drug release for F10 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.4 0.4 4.0 
2 1.5 1.504 15.04 
3 1.8 1.815 18.15 
4 2.1 2.118 21.18 
5 2.8 2.821 28.21 
6 3.0 3.028 30.28 
7 3.4 3.430 34.30 
8 3.9 3.934 39.34 
9 4.2 4.239 42.39 
10 4.8 4.842 48.42 
11 4.9 4.948 49.48 
12 5.3 5.349 53.49 
13 5.8 5.853 58.53 
14 5.9 5.958 59.58 
15 6.3 6.359 63.59 
16 6.6 6.663 66.63 
17 6.8 6.866 68.66 
18 7.1 7.168 71.68 
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Table:20 In vitro drug release for F11 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.40 0.40 4.0 
2 0.5 0.504 05.04 
3 0.8 0.805 08.05 
4 1.1 1.108 11.08 
5 1.2 1.211 12.11 
6 1.5 1.512 15.12 
7 1.9 1.915 19.15 
8 2.4 2.419 24.19 
9 2.5 2.524 25.24 
10 3.0 3.025 30.25 
11 3.1 3.130 31.30 
12 3.3 3.331 33.31 
13 3.9 3.933 39.33 
14 4.0 4.039 40.39 
15 4.2 4.240 42.40 
16 4.6 4.642 46.42 
17 4.7 4.746 47.46 
18 5.0 5.047 50.47 
19 5.1 5.150 51.50 
20 5.3 5.351 53.51 
21 5.7 5.753 57.53 
22 5.8 5.857 58.57 
23 6.1 6.158 61.58 
24 6.9 6.961 69.61 
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Table:21 In vitro drug release for F12 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.8 0.8 8.0 
2 1.0 1.008 10.08 
3 1.5 1.510 15.10 
4 1.6 1.615 16.15 
5 1.8 1.816 18.16 
6 2.3 2.318 23.18 
7 2.6 2.623 26.23 
8 2.8 2.826 28.26 
9 3.3 3.328 33.28 
10 3.5 3.533 35.33 
11 3.9 3.935 39.35 
12 4.0 4.039 40.39 
13 4.4 4.440 44.40 
14 4.6 4.644 46.44 
15 5.1 5.146 51.46 
16 5.5 5.551 55.51 
17 6.0 6.055 60.55 
18 6.6 6.660 66.60 
19 6.7 6.766 67.66 
20 6.9 6.967 69.67 
21 7.1 7.169 71.69 
22 7.2 7.271 72.71 
23 7.8 7.872 78.72 
24 8.3 8.378 83.78 
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Table:22 In vitro drug release for F13 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 1.2 1.20 12.0 
2 1.9 1.912 19.12 
3 2.1 2.119 21.19 
4 2.3 2.321 23.21 
5 2.4 2.423 24.23 
6 2.9 2.924 29.24 
7 3.1 3.129 31.29 
8 3.9 3.931 39.31 
9 4.1 4.139 41.39 
10 4.4 4.441 44.41 
11 4.8 4.844 48.44 
12 5.0 5.048 50.48 
13 5.2 5.250 52.50 
14 5.4 5.452 54.52 
15 5.7 5.754 57.54 
16 5.8 5.857 58.57 
17 6.4 6.458 64.58 
18 6.8 6.864 68.64 
19 6.9 6.968 69.68 
20 7.5 7.569 75.69 
21 7.9 7.975 79.75 
22 8.4 8.479 84.79 
23 8.6 8.684 86.84 
24 9.0 9.086 90.86 
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Table:23 In vitro drug release for F14 
Time 
(Hrs) 
Amount of 
drug release 
(mg) 
Cumulative 
amount of drug 
release (mg) 
Cumulative % 
drug release 
(%) 
1 0.5 0.5 5.0 
2 1.0 1.005 10.05 
3 1.6 1.610 16.10 
4 1.8 1.816 18.16 
5 2.3 2.318 23.18 
6 2.9 2.923 29.23 
7 3.1 3.129 31.29 
8 3.2 3.231 32.31 
9 3.5 3.532 35.32 
10 3.9 3.935 39.35 
11 4.2 4.239 42.39 
12 4.4 4.442 44.42 
13 4.9 4.944 49.44 
14 5.0 5.049 50.49 
15 5.2 5.250 52.50 
16 5.7 5.752 57.52 
17 6.0 6.057 60.57 
18 6.2 6.260 62.60 
19 6.9 6.962 69.62 
20 7.3 7.369 73.69 
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In vitro release study of zidovudine niosomes 
 
Table:24 
 
Formulation 
code 
 
Surfactant: 
Cholesterol 
(µM) 
 
Surfactant 
used 
 
Total release 
period 
(Hrs) 
Cumulative 
percentage 
drug release 
(%) 
F1 100:100 Span 20 16 61.58 
F2 200:100 Span 20 17 72.69 
F3 300:100 Span 20 16 67.64 
F4 100:200 Span 20 24 59.57 
F5 200:200 Span 20 24 71.65 
F6 300:200 Span 20 24 81.97 
F7 400:200 Span 20 14 70.63 
F8 100:100 Tween 20 16 65.61 
F9 200:100 Tween 20 18 79.74 
F10 300:100 Tween 20 18 71.68 
F11 100:200 Tween 20 24 69.61 
F12 200:200 Tween 20 24 83.78 
F13 300:200 Tween 20 24 90.86 
F14 400:200 Tween 20 20 73.69 
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In vitro drug release was carried out for 24 hours using phosphate buffer as 
diffusion medium. It was found to be biphasic, and the release was controlled by lipid 
bilayer and dialysis membrane. Incorporation of cholesterol affected the release rate 
of encapsulated drug. In vitro drug release characteristics for formulations containing 
two different surfactants were compared. Zidovudine niosomes were tried with two 
different surfactant and cholesterol concentrations.   
 
Drug release from formulations F1, F2 and F3 were found to be 61.58%, 
72.69%, and 67.64% in 16 hrs, 17 hrs and 16 hrs respectively. The release was not 
extended upto 24 hrs, because those formulations contained low cholesterol 
concentration.  
 
 Quantity of cholesterol was increased to 200µM in formulations F4, F5, F6 and 
F7 and release was achieved to 59.57% in 24 hrs, 71.65% in 24 hrs, 81.97% in 24 
hours and 70.63% in 14 hrs. Except F7, release from other formulation was extended 
to 24 hrs. This is due to higher concentration of surfactant in formulation F7. Extended 
release was achieved but those formulations were not satisfied with percentage drug 
release. Higher release was found to be 81.83%. This is due to the water insoluble 
nature of span 20. 
 
Due to lower concentration of cholesterol in formulations F8, F9 and F10 , the 
release were 65.61% 16 hrs, 79.48% at 18 hrs and 71.68% at 18 hrs respectively. 
Formulations F11, F12, F13 and F14 contained 200 µM of cholesterol showed 69.61% of 
drug release in 24 hrs,  83.78% of drug release in 24 hrs, 90.86% of drug release in 24 
hrs and 73.69% of drug release in 20 hrs. Higher release of 90.86% was found in 
formulation contained 300:200 µmol ratio of surfactant and cholesterol. So 
formulation F13 (300:200 µmol) was considered as optimized formulation.  
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Table:25 In vitro drug release studies for formulations containing Span 20 
 
Time  
(Hrs) 
Cumulative percentage drug release (%) 
F1 F2 F3 F4 F5 F6 F7 
1 3.0 8.0 3.0 2.0 2.0 5.0 6.0 
2 8.03 10.08 6.03 4.02 5.02 7.05 8.06 
3 15.08 11.10 14.06 9.04 7.05 10.07 15.08 
4 16.15 15.11 16.14 10.09 8.07 15.10 17.15 
5 22.16 22.15 23.16 13.10 13.08 16.15 20.17 
6 24.22 26.22 27.23 14.13 15.13 18.16 21.20 
7 28.24 30.26 29.27 18.14 19.15 25.18 26.21 
8 33.28 32.30 34.29 22.18 25.19 28.25 33.26 
9 35.33 33.22 48.34 25.22 26.25 33.28 34.33 
10 41.35 37.33 49.48 26.25 30.26 34.33 40.34 
11 43.41 42.37 51.49 30.26 31.30 39.34 49.40 
12 47.43 48.42 54.51 31.30 33.31 41.39 55.49 
13 49.47 54.48 55.54 32.31 36.33 45.41 63.55 
14 53.48 56.51 57.55 35.32 38.36 47.45 70.63 
15 58.53 68.56 64.57 36.35 42.38 55.47 - 
16 61.58 69.68 67.64 38.36 43.42 57.55 - 
17 - 72.69 - 39.38 45.43 61.57 - 
18 - - - 40.39 48.45 66.61 - 
19 - - - 43.40 51.48 69.66 - 
20 - - - 47.43 55.51 72.69 - 
21 - - - 49.47 60.55 74.72 - 
22 - - - 50.49 63.60 76.74 - 
23 - - - 57.50 65.63 79.76 - 
24 - - - 59.57 71.65 81.97 - 
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Fig:22 Comparative in vitro release study of zidovudine niosomal formulations 
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Table:26 In vitro drug release studies for formulations containing Tween 20 
 
Time  
(Hrs) 
Cumulative percentage drug release (%) 
F1 F2 F3 F4 F5 F6 F7 
1 4.0 9.0 4.0 4.0 8.0 12.0 5.0 
2 8.04 14.09 15.04 05.04 10.08 19.12 10.05 
3 11.08 15.14 18.15 08.05 15.10 21.19 16.10 
4 19.11 19.15 21.18 11.08 16.15 23.21 18.16 
5 22.19 24.19 28.21 12.11 18.16 24.23 23.18 
6 34.22 29.24 30.28 15.12 23.18 29.24 29.23 
7 36.34 32.29 34.30 19.15 26.23 31.29 31.29 
8 39.36 35.32 39.34 24.19 28.26 39.31 32.31 
9 41.39 36.35 42.39 25.24 33.28 41.39 35.32 
10 45.41 41.36 48.42 30.25 35.33 44.41 39.35 
11 47.45 48.41 49.48 31.30 39.35 48.44 42.39 
12 50.47 51.48 53.49 33.31 40.39 50.48 44.42 
13 53.5 53.51 58.53 39.33 44.40 52.50 49.44 
14 59.53 58.53 59.58 40.39 46.44 54.52 50.49 
15 61.59 61.58 63.59 42.40 51.46 57.54 52.50 
16 65.61 68.61 66.63 46.42 55.51 58.57 57.52 
17 - 74.68 68.66 47.46 60.55 64.58 60.57 
18 - 79.74 71.68 50.47 66.60 68.64 62.60 
19 - - - 51.50 67.66 69.68 69.62 
20 - - - 53.51 69.67 75.69 73.69 
21 - - - 57.53 71.69 79.75 - 
22 - - - 58.57 72.71 84.79 - 
23 - - - 61.58 78.72 86.84 - 
24 - - - 69.61 83.78 90.86 - 
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Fig:23 Comparative in vitro release study of zidovudine niosomal formulations 
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7.4.4. Scanning electron microscopy 
 The surface characteristics of zidovudine niosomal formulation were studied 
by scanning electron microscopy. SEM image of prepared niosome formulation 
shows that the coating of surfactant cholesterol mixture on drug particles. Some 
particles in the images are broken, which might be due to handling and processing. 
Most of the vesicles are spherical and discrete sharp boundaries. The appearance of 
niosome vesicles in scanning electron micrograph is smooth, which indicates a thin 
and uniform coating over the drug. Based on the scale of micrograph, no significant 
change in size of particles is seen. The observation clearly shows that, there is no 
aggregation between the particles, due to surfactant coating. 
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7.4.5. Zeta potential 
 The addition of membrane additives affects zeta potential value depending on 
the type of membrane additives. Zeta potential of optimized zidovudine niosome 
formulation was measured and found to -27.3 mv. The negative zeta potential 
observed with niosomes reflects the presence of negatively charged DCP on the 
surface of vesicles. The obtained result of the zeta potential of the prepared 
formulation indicates particles in the formulation remains suspended and so were 
found to be stable. The particles being suspended. The formulation was found to be 
very effective for parenteral administration.     
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7.4.6. Sterility test 
 The optimized Zidovudine niosomal formulation was subjected to sterility test. 
The test was carried out as per I.P specification. Both Soya bean casein digest 
medium (SCDM) and Fluid thioglycollate medium (FTM) were used. The method 
followed is Method A – Membrane filtration method. The positive control was 
prepared from standardised Bacillus subtilis suspension. The samples dipped in 
SCDM and FTM incubated for 14 days. The absence of turbidity of the test indicates 
the sterility of the formulation and passed the sterility test.   
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7.4.7. Stability studies 
The optimized zidovudine niosomal formulation (F13) was subjected to 
stability study for three months at 40C, room temperature and 450C/75%RH. At the 
interval of one month the niosomes evaluated for in vitro release and entrapment 
efficiency. The stability study shows that niosomal formulations are more stable at 
4°C (refrigerator) when compared to room temperature and at 450C/75%RH 
 
Table:27 Entrapment efficiency data 
Temperature 
Percentage 
entrapment after  
one month (%) 
Percentage 
entrapment after   
two months (%) 
Percentage 
entrapment after 
three months (%) 
 
4°C 
 
90 
 
89 
 
89 
Room 
temperature 
 
87 
 
85 
 
80 
 
45°C/75% RH 
 
84 
 
81 
 
74 
 
 
Table:28 In vitro release data 
Temperature 
Cumulative % 
release after one 
month (%) 
Cumulative % 
release after two 
months (%) 
Cumulative % 
release after three 
months (%) 
 
4°C 
 
89.87 
 
88.84 
 
87.83 
Room 
temperature 
 
85.83 
 
82.80 
 
78.77 
 
45°C/75% RH 
 
81.79 
 
75.73 
 
70.66 
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Table:29 In vitro data for optimized formulation F13 stability study at 40C 
Time 
(Hrs) 
Cumulative % drug release 
1st month (%) 2nd month (%) 3rd month (%) 
1 7.0 4.0 8.0 
2 9.07 8.04 10.08 
3 13.09 13.08 11.10 
4 19.13 15.13 17.11 
5 24.19 16.15 19.17 
6 25.24 22.16 23.19 
7 32.24 25.22 24.23 
8 39.32 29.25 28.24 
9 48.39 35.29 31.28 
10 50.48 42.35 32.31 
11 54.50 44.42 35.32 
12 56.54 49.44 39.35 
13 60.56 50.49 44.39 
14 63.60 53.50 45.44 
15 65.63 59.53 52.44 
16 69.65 61.59 59.52 
17 72.69 63.61 63.59 
18 75.72 70.63 64.63 
19 77.75 72.70 68.64 
20 81.77 74.72 74.68 
21 82.81 78.74 75.74 
22 83.82 80.78 79.75 
23 87.83 84.80 83.79 
24 89.87 88.84 87.83 
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Fig:27 STABILITY STUDY RELEASE DATA FOR FORMULATION F13 
AFTER THREE MONTHS AT 4°C 
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Table:30 In vitro data for optimized formulation F13 stability study at 
Room temperature 
Time 
(Hrs) 
Cumulative % drug release 
1st month (%) 2nd month (%) 3rd month (%) 
1 7.0 5.0 5.0 
2 9.07 7.05 7.05 
3 12.09 13.07 14.07 
4 16.12 17.13 20.14 
5 19.08 24.17 22.20 
6 23.19 29.24 26.22 
7 24.23 31.29 27.26 
8 29.24 34.31 32.27 
9 33.29 39.34 34.32 
10 34.33 45.39 37.34 
11 39.34 47.45 39.37 
12 41.39 49.47 42.38 
13 45.41 51.49 44.42 
14 47.45 53.51 48.42 
15 49.47 56.53 50.48 
16 50.49 61.56 51.50 
17 62.50 63.61 58.51 
18 63.62 68.63 60.58 
19 69.63 69.68 66.60 
20 70.69 71.69 67.66 
21 76.70 72.71 69.67 
22 79.76 77.72 74.69 
23 83.79 80.77 77.74 
24 85.83 82.80 78.77 
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Fig:28 STABILITY STUDY RELEASE DATA FOR FORMULATION F13 
AFTER THREE MONTHS AT ROOM TEMPERATURE 
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Table:31 In vitro data for optimized formulation F13 stability study at 
45°c/75%RH 
Time 
(Hrs) 
Cumulative % drug release 
1st month (%) 2nd month (%) 3rd month (%) 
1 5.0 6.0 4.0 
2 9.05 11.06 8.04 
3 16.09 13.11 10.08 
4 18.16 17.13 13.10 
5 22.18 21.17 14.13 
6 24.22 22.21 19.14 
7 27.24 26.22 25.19 
8 29.27 28.26 28.25 
9 33.29 30.28 30.28 
10 37.33 31.30 32.30 
11 38.37 34.31 35.32 
12 44.38 40.34 36.35 
13 45.44 42.40 40.36 
14 49.45 48.42 41.40 
15 55.49 51.48 43.41 
16 57.55 53.51 46.43 
17 62.57 57.53 48.45 
18 69.62 59.57 49.48 
19 70.69 61.59 54.49 
20 74.70 63.61 55.54 
21 76.74 67.63 61.55 
22 77.76 68.67 64.61 
23 79.77 73.68 66.64 
24 81.79 75.73 70.66 
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Fig:29 STABILITY STUDY RELEASE DATA FOR FORMULATION F13 
AFTER THREE MONTHS AT 45°C /75% RH 
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7.4.8. Kinetics of drug release 
 The optimized formulation F13 was subjected to graphical treatment to assess 
the kinetics of drug release. 
 
ZERO ORDER PLOT 
 The optimized formulation F13 is most suitable parenteral administration as it 
founds to be good in the in vitro release kinetic study. The zero order plot obtained by 
plotting cumulative percentage drug release versus time. The regression value is 
0.9887.      
   
Fig:30 Zero order plot for formulation F13  
 
 
 
 
Slope = 3.3753 
Regression = 0.9887 
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FIRST ORDER PLOT 
 The first order plot was obtained by plotting log cumulative percentage of 
drug remaining versus time. The regression value is 0.889. 
 
 
 
Fig:31 First order plot for formulation F13  
 
 
 
Slope = -0.035 
Regression = 0.889 
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HIGUCHI PLOT 
 The Higuchi plot was made by plotting cumulative percentage drug release 
versus square root of time. The regression value is 0.9539. It confirms that the release 
is diffusion mediated.   
 
 
Fig:32 Higuchi plot for formulation F13 
 
 
 
Slope = 1.8921 
Regression = 0.9539 
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KORSEMEYER PLOT 
 The graph was obtained by log cumulative percentage drug release versus log 
time. The n value is 0.6579. The n value (0.45 < n < 0.89) indicates that the drug 
release follows anomalous (non fickian) diffusion. 
 
 
 
 
Fig:33  Korsemeyer plot for formulation F13 
 
 
 
n = 0.6579 
Regression = 0.9761 
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Fig:24 Scanning Electron Microscopy 
 
 
 
 
 
  
Fig:25 Observation of the sterility test done in soyabean casein digest medium 
(SCDM). 
 
 
 
          
                                                 
 P – Positive control 
                                                  N – Negative control 
                                                  A - Sample 
 
 
 
 
  
Fig:26 Observation of the sterility test done in fluid thioglycollate medium 
(FTM) 
 
 
 
 
                                                       
 P – Positive Control 
 N – Negative Control 
 A - Sample 
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8. CONCLUSION 
 
In this study niosomal drug delivery system was developed using non-ionic 
surfactant incorporating Zidovudine by Thin film hydration technique. The prepared 
niosomal vesicles were quite stable. 
 
The formulation was subjected to Entrapment efficiency, Scanning electron 
microscopy, Invitro release, and Zeta potential analysis. From the results of 
experimental investigation, we concluded that, formulation F13 containing drug with 
300:200 µmol (surfactant:cholesterol) ratio was showing higher percentage 
entrapment with desired sustained release of zidovudine. Hence formulation F13 was 
considered as optimized formulation.  
 
Invitro release from optimized zidovudine niosomal formulation (F13) showed 
extended release for 24 hours.  
 
SEM image revealed the vesicles are exist spherical shape and uniform in size. 
Scanning electron micrograph shows there is no aggregation between the particles.  
 
Negative zeta potential value was observed in zeta potential analysis. This 
confirmed the presence of negative charge inducing agent in formulation. 
 
The formulation was checked for sterility as per I.P specification. The 
optimized formulation passes the sterility test.     
 
Stability study was carried out for the period of three months at various 
storage conditions. The results showed that the formulation remains stable at 4°c.  
 
The optimized formulation was found to follow zero order release pattern 
which was revealed by the linearity shown from the plot of Time Vs cumulative 
percentage drug release. From the drug release kinetic studies, we concluded that the 
drug was released from niosome by a zero order diffusion controlled mechanism. 
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